JPH0812696A - New 16-membered ring macrolide derivative and its efficient production - Google Patents

New 16-membered ring macrolide derivative and its efficient production

Info

Publication number
JPH0812696A
JPH0812696A JP6145125A JP14512594A JPH0812696A JP H0812696 A JPH0812696 A JP H0812696A JP 6145125 A JP6145125 A JP 6145125A JP 14512594 A JP14512594 A JP 14512594A JP H0812696 A JPH0812696 A JP H0812696A
Authority
JP
Japan
Prior art keywords
group
compound
formula
och
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6145125A
Other languages
Japanese (ja)
Inventor
Keiichi Ajito
慶一 味戸
Nobue Kikuchi
伸江 菊地
Osamu Hara
修 原
Masayuki Shibahara
聖至 柴原
Shigeharu Inoue
重治 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Priority to JP6145125A priority Critical patent/JPH0812696A/en
Priority to CA002127578A priority patent/CA2127578A1/en
Priority to ES94110679T priority patent/ES2115816T3/en
Priority to EP94110679A priority patent/EP0633266B1/en
Priority to AT94110679T priority patent/ATE165604T1/en
Priority to CN94115983A priority patent/CN1046534C/en
Priority to US08/271,996 priority patent/US5602106A/en
Priority to DE69409874T priority patent/DE69409874T2/en
Priority to KR1019940016581A priority patent/KR100360568B1/en
Publication of JPH0812696A publication Critical patent/JPH0812696A/en
Priority to CN98116380A priority patent/CN1093134C/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain a new compound showing excellent effect in vivo as an antibacterial agent against gram-positive bacteria. CONSTITUTION:This compound is expressed by formula I (R<1> is H 1-3C straight- chain alkyl; R<2> is H or an OH-protecting group; R<3> is H or a 2-5C aliphatic acyl). The compound of formula I is obtained by using a compound of formula II (R<4> is a 2-5C aliphatic acyl) (salt) as a starting raw material. The hydroxyl group at the 3'' position of the compound is methylated and the hydroxyl group at the 3 position of the lactone ring is acylated.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明はグラム陽性菌に有効な新
規16員環マクロリド誘導体とそれらの効率的製造法に
関する。
TECHNICAL FIELD The present invention relates to a novel 16-membered ring macrolide derivative effective against Gram-positive bacteria and an efficient method for producing the same.

【0002】[0002]

【従来の技術】臨床における有用性を向上させることを
目的として、現在各国のグループが積極的に16員環マ
クロリド抗生物質の誘導体研究を行なっている。それら
の内のある種の誘導体は、特定の水酸基をアシル化する
ことによりin vitroの抗菌活性及び/或いは体内動態を
改善しようとして合成されたものである。しかしながら
最近の誘導体研究の主流は、16員環ラクトンへの置換
されたアミノ基の導入(ジャーナル・オブ・アンチビオ
チックス, 44(4), 448(1991))、又は特定の水酸基のデ
オキシ化(ジャーナル・オブ・アンチビオチックス, 45
(1), 144(1992))或いはアルキル化に集中してきた。
2. Description of the Related Art At present, groups in various countries are actively conducting derivative research on 16-membered macrolide antibiotics for the purpose of improving their clinical utility. Certain of these derivatives were synthesized in an attempt to improve in vitro antibacterial activity and / or pharmacokinetics by acylating a specific hydroxyl group. However, the mainstream of recent research on derivatives has been the introduction of substituted amino groups into 16-membered ring lactones (Journal of Antibiotics, 44 (4), 448 (1991)), or deoxylation of specific hydroxyl groups ( Journal of Antibiotics, 45
(1), 144 (1992)) or focused on alkylation.

【0003】本発明者らは、エリスロマイシンの構成糖
の一つであるL-クラジノースの化学構造を発想の基礎に
誘導体研究を重ね、ラクトン環の9位がsp3炭素であり
中性糖部分である3"位の水酸基がメチル化されている1
6員環マクロリド誘導体(4"位は遊離の水酸基であって
もアシル化された水酸基であってもよい)を、グリコシ
ル化反応を経由することによって調製し、それらが優れ
た抗菌活性を有することを明らかにし特許出願した(特
願平5-169418)。一方で、9位がsp2炭素であり3"位の
水酸基がメチル化されている16員環マクロリド誘導体
の合成及び抗菌活性については、本発明者らの出願(特
願平5-3545)に先立ち既に報告がある(ケミストリー・
レターズ, 769(1977))。
The inventors of the present invention conducted derivative research based on the idea of the chemical structure of L-cladinose, which is one of the constituent sugars of erythromycin, and found that the 9-position of the lactone ring was the sp 3 carbon and the neutral sugar moiety. The hydroxyl group at the 3 "position is methylated 1
A 6-membered ring macrolide derivative (the 4 "position may be a free hydroxyl group or an acylated hydroxyl group) is prepared by way of a glycosylation reaction, and they have excellent antibacterial activity. On the other hand, regarding the synthesis and antibacterial activity of the 16-membered ring macrolide derivative in which the 9-position is sp 2 carbon and the hydroxyl group at the 3 "-position is methylated, There is already a report prior to the application of the present inventors (Japanese Patent Application No. 5-3545) (Chemistry.
Letters, 769 (1977)).

【0004】一方当社は、天然より得られる16員環マ
クロリド抗生物質であるメデマイシン(ミデカマイシン
1)(ジャーナル・オブ・アンチビオチックス, 24
(7), 452 (1971))のin vivo効果を改善することを目的
に、誘導体研究を続けていた。それらの研究の過程にお
いて数種の優れたメデマイシン誘導体を造出しており、
その中の一つとして中性糖部分である3"位の水酸基がメ
チルチオメチル(-CH2SCH3)化された16員環マクロリ
ド誘導体、即ち本願における鍵中間体の合成を既に発表
していた(ジャーナル・オブ・アンチビオチックス, 33
(1), 61(1980))。他方糖質化学において、2級水酸基
に導入されたメチルチオメチル基が還元を受け、結果と
してメトキシ基に化学変換される事実は1960年代より知
られていた(カーボハイドレート・リサーチ, 7, 474(1
968))。
On the other hand, our company is a 16-member ring
Chloride antibiotic medemycin (midecamycin
A1) (Journal of Antibiotics,twenty four
(7), 452 (1971))in vivoAim to improve the effect
I continued to study derivatives. In the process of those studies
Have produced several excellent medemycin derivatives,
One of them is the hydroxyl group at the 3 "position, which is the neutral sugar moiety.
Tylthiomethyl (-CH2SCH3) Transformed 16-member ring macro
Derivative, that is, the synthesis of the key intermediate in the present application has already been announced.
(Journal of Antibiotics,33
(1), 61 (1980)). On the other hand, in sugar chemistry, secondary hydroxyl groups
The methylthiomethyl group introduced into
The fact that it is chemically converted to a methoxy group has been known since the 1960s.
(Carbo hydrate research,7, 474 (1
968)).

【0005】ところで、ラクトン環の3位水酸基が遊離
である16員環マクロリド抗生物質を出発原料として用
いて、中性糖部分である4"位の水酸基及び3"位の水酸基
に順次アルキル基を導入する合成法に関しては、本発明
者らが既に特許出願した(特願平5-206731)。
By the way, a 16-membered macrolide antibiotic in which the 3-position hydroxyl group of the lactone ring is free is used as a starting material, and an alkyl group is sequentially added to the neutral sugar moiety 4 "-position hydroxyl group and 3" -position hydroxyl group. Regarding the synthetic method to be introduced, the present inventors have already applied for a patent (Japanese Patent Application No. 5-206731).

【0006】[0006]

【発明が解決しようとする課題】中性糖部分である3"位
の水酸基がメチル化されていて、4"位の水酸基が遊離で
あるか又はアシル化されている16員環マクロリド誘導
体を、グリコシル化反応を経由することなく調製する方
法については、9位の構造の如何にかかわらず現在まで
のところ全く知られていない。そこで特にラクトン環の
9位がsp3炭素である当該化合物を、グリコシル化反応
を経由することなく調製する方法の発見が期待されてい
る。
A 16-membered ring macrolide derivative in which the hydroxyl group at the 3 "position, which is a neutral sugar moiety, is methylated, and the hydroxyl group at the 4" position is free or is acylated, Up to now, no method for preparing it without going through a glycosylation reaction is known regardless of the structure at the 9-position. Therefore, in particular, it is expected to find a method for preparing the compound in which the 9-position of the lactone ring has sp 3 carbon, without going through the glycosylation reaction.

【0007】[0007]

【課題を解決するための手段】本発明者らは上記の期待
に応えるべく合成化学的研究を重ね、ラクトン環の3位
水酸基にアシル基を有する天然の16員環マクロリド抗
生物質を出発原料として用いて、3"位のメチルチオメチ
ルエーテル合成中間体を経由し、ラクトン環の3位水酸
基がアシル化されており中性糖部分である3"位の3級水
酸基がメチル化された16員環マクロリド誘導体を、グ
リコシル化反応を経由することなく効率的に製造する方
法を確立することに成功した。しかも本発明製造法を用
いて調製した誘導体は、臨床上重要なグラム陽性菌の発
育を阻止するとともに、優れたinvivo効果を有すること
を見い出し、本発明を完成した。さらに本発明に至る研
究過程において、16員環マクロリド誘導体のラクトン
環9位の水酸基に関する優れた保護・脱保護法を見い出
した。
Means for Solving the Problems The present inventors have repeatedly conducted synthetic chemical research in order to meet the above-mentioned expectations, using a natural 16-membered macrolide antibiotic having an acyl group at the 3-hydroxy group of the lactone ring as a starting material. A 16-membered ring in which the hydroxyl group at the 3-position of the lactone ring is acylated and the tertiary hydroxyl group at the 3 "-position, which is a neutral sugar moiety, is methylated via a methylthiomethyl ether synthetic intermediate at the 3-position We have succeeded in establishing a method for efficiently producing macrolide derivatives without going through a glycosylation reaction. Furthermore, the inventors have found that the derivative prepared using the production method of the present invention inhibits the growth of clinically important Gram-positive bacteria and has an excellent in vivo effect, and completed the present invention. Further, in the course of research leading to the present invention, an excellent protection / deprotection method for the hydroxyl group at the 9-position of the lactone ring of the 16-membered macrolide derivative was found.

【0008】第一の本発明の要旨とするところは、新規
化合物としての次の式(I)
The gist of the first aspect of the present invention lies in the following formula (I) as a novel compound.

【化4】 [Chemical 4]

【0009】[式中、R1は炭素数1〜3の直鎖のアルキ
ル基であり、R2は水素原子又は水酸基を修飾(或いは保
護)する置換基であり、R3は水素原子又は炭素数2〜5
の直鎖又は分枝鎖の脂肪族アシル基]で表される化合
物、又はその薬学的に許容し得る塩に関するものであ
る。
[In the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms, R 2 is a hydrogen atom or a substituent for modifying (or protecting) a hydroxyl group, and R 3 is a hydrogen atom or a carbon atom. Number 2-5
A linear or branched aliphatic acyl group of the above], or a pharmaceutically acceptable salt thereof.

【0010】第二の本発明の要旨とするところは、次の
式(II)
The gist of the second invention is that the following formula (II)

【化5】 Embedded image

【0011】[式中、R1は炭素数1〜3の直鎖のアルキ
ル基であり、R4は炭素数2〜5の直鎖又は分枝鎖の脂肪
族アシル基]で表される化合物、又はその塩を出発原料
として用いて、3"位のメチルチオメチルエーテル合成中
間体を経由し、次の式(III)
A compound represented by the formula: wherein R 1 is a linear alkyl group having 1 to 3 carbon atoms and R 4 is a linear or branched aliphatic acyl group having 2 to 5 carbon atoms. , Or a salt thereof as a starting material and passing through a methylthiomethyl ether synthetic intermediate at the 3 ”position to give the following formula (III):

【化6】 [Chemical 6]

【0012】[式中、R1は炭素数1〜3の直鎖のアルキ
ル基であり、R2は水素原子又は水酸基を修飾(或いは保
護)する置換基であり、R4は炭素数2〜5の直鎖又は分
枝鎖の脂肪族アシル基]で表される化合物、又はその塩
を効率良く化学合成することのできる新規製造法に関す
るものである。本発明による一般式(III)で表される
化合物は、工程図1に示す方法により以下の様に製造さ
れる(なお、一般式(III)で表される化合物は、工程
図1においては式(VIII)又は式(IX)によって表され
ている)。
[In the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms, R 2 is a hydrogen atom or a substituent for modifying (or protecting) a hydroxyl group, and R 4 is 2 to 2 carbon atoms. 5 straight-chain or branched-chain aliphatic acyl group] or a salt thereof, which is capable of efficiently chemically synthesizing a compound. The compound represented by the general formula (III) according to the present invention is produced by the method shown in the process chart 1 as follows (the compound represented by the general formula (III) is represented by the formula in the process chart 1). (VIII) or formula (IX)).

【0013】[0013]

【化7】 [Chemical 7]

【0014】[0014]

【化8】 Embedded image

【0015】16員環マクロリド誘導体において中性糖
部分である3"位の水酸基に選択的にメチル基を導入した
化合物が、抗菌剤としていかに有望であるかについては
先願(特願平5-169418)において記述した。一方16員
環マクロリド化合物、特にロイコマイシン類に関して
は、特別な合成中間体を経由することなく水酸基を直接
アルキル化しようとすると、困難な問題を生ずることが
知られている(特願平5-206731)。本願は、ラクトン環
の3位水酸基と中性糖部分である4"位の水酸基が共にア
シル化された化合物に関して、中性糖部分である3"位の
3級水酸基に対し間接的にメチル基を導入する合成法に
ついて記述されており、本発明製造法等により調製した
新規誘導体の抗菌活性及びin vivo効果等についても記
載されている。
[0016] Regarding the promising antibacterial agent, a compound in which a methyl group is selectively introduced into the hydroxyl group at the 3 "-position of the neutral sugar moiety in the 16-membered ring macrolide derivative is a prior application (Japanese Patent Application No. 169418). On the other hand, for 16-membered ring macrolide compounds, especially leucomycins, it is known that direct alkylation of the hydroxyl group without going through a special synthetic intermediate causes a difficult problem. (Japanese Patent Application No. 5-206731). The present application relates to a compound in which the hydroxyl group at the 3-position of the lactone ring and the hydroxyl group at the 4 "position, which is the neutral sugar moiety, are both acylated, and the 3" position at the 3 "position, which is the neutral sugar moiety. A synthetic method in which a methyl group is indirectly introduced into a primary hydroxyl group is described, and the antibacterial activity and in vivo effect of the novel derivative prepared by the production method of the present invention are also described.

【0016】合成法を述べるに先立ち、16員環マクロ
リド誘導体におけるラクトン環9位の水酸基に関する構
造とin vitroの抗菌活性及び薬物動態との相関について
簡単に触れる。当該誘導体において、9位の水酸基だけ
を選択的にアシル化、例えばアセチル化した化合物は、
原体と比較してin vitroの抗菌活性が同等か或いは僅か
に減弱し、同活性が明確に増強された報告は殆どなされ
ていない。一方小動物、例えば実際にマウスを用いてin
vivo試験を行なうと、9位水酸基だけがアセチル化さ
れた化合物は原体と比較して、体内動態或いは感染治療
効果が向上する誘導体もあれば向上しない化合物もあ
り、9位の構造の違いによるin vivo効果への影響は、
該当する16員環マクロリド誘導体の構造それ自身に大
きく関与している。
Prior to describing the synthetic method, the structure of the 16-membered macrolide derivative relating to the hydroxyl group at the 9-position of the lactone ring and the correlation with the in vitro antibacterial activity and pharmacokinetics will be briefly described. In the derivative, a compound in which only the 9-position hydroxyl group is selectively acylated, for example, acetylated, is
The in vitro antibacterial activity is equivalent to or slightly attenuated as compared with that of the drug substance, and there is almost no report that the activity is clearly enhanced. On the other hand, small animals, such as actually using a mouse in
In vivo tests showed that some compounds in which only the 9-position hydroxyl group was acetylated had improved derivative pharmacokinetics or infection treatment effects, while others did not, compared to the drug substance. The impact on in vivo effects is
It is greatly involved in the structure itself of the corresponding 16-membered macrolide derivative.

【0017】然るに16員環マクロリド誘導体を実際に
効率良く製造する合成法をデザインするにあたっては、
一つの鍵反応で、9位の水酸基が何らかの置換基で修飾
された化合物と、9位の水酸基が遊離である化合物とを
作り分けることのできる製造ルートを構築することが望
まれる。
Therefore, in designing a synthetic method for actually producing a 16-membered ring macrolide derivative efficiently,
It is desired to construct a production route capable of separately producing a compound in which the 9-position hydroxyl group is modified with a substituent and a compound in which the 9-position hydroxyl group is free, by one key reaction.

【0018】ところでアシル基、例えばアセチル基を9
位の水酸基の保護基と考え製造法をデザインすれば、保
護工程における反応条件の上から比較的好都合である。
しかしながら16員環マクロリド誘導体に関する化学合
成において、他の副反応を完全に抑制し収率良く9位の
水酸基に結合したアシル基を除去し、遊離の水酸基を再
生する方法はあまり知られていない。一方で16員環マ
クロリド誘導体において、放線菌を用いた微生物変換を
行なうことにより、ラクトン環の9位水酸基に結合した
アセチル基を除去する例も報告されている(ジャーナル
・オブ・ファーメンテーション・アンド・ビオエンジニ
アリング, 71(5), 370(1991))が、その変換率には改善
の余地が残されている様である。
By the way, an acyl group such as acetyl group
If the manufacturing method is designed by considering it as a protecting group for the hydroxyl group at the position, it is relatively convenient from the viewpoint of reaction conditions in the protecting step.
However, in the chemical synthesis of the 16-membered ring macrolide derivative, a method of completely suppressing other side reactions, removing the acyl group bonded to the hydroxyl group at the 9-position, and regenerating the free hydroxyl group is not well known. On the other hand, in the 16-membered macrolide derivative, an example of removing the acetyl group bonded to the 9-position hydroxyl group of the lactone ring by carrying out microbial conversion using actinomycetes has been reported (Journal of Fermentation. Andbio Engineering, 71 (5), 370 (1991)), but there seems to be room for improvement in the conversion rate.

【0019】本発明者らは当該研究を通じ、あくまで穏
和な条件で16員環マクロリド誘導体の中性糖部分であ
る3"位の3級水酸基にメチル基を導入する合成法に加
え、同マクロリド誘導体におけるラクトン環の9位水酸
基に関わる定量的保護・脱保護法を見い出したので、工
程図1に沿って以下にその詳細を述べる。なお、工程図
1においては、その製造法の一例としてラクトン環の9
位がsp3炭素である天然の16員環マクロリド抗生物質
を出発原料として用いているが、9位がカルボニル基で
ある化合物を出発原料として用いた場合も同様の方法論
によって、間接的に3"位の3級水酸基に効率良くメチル
基を導入することが可能である。
Through the research, the present inventors have added to the synthetic method of introducing a methyl group into the tertiary hydroxyl group at the 3 "-position, which is the neutral sugar moiety of the 16-membered ring macrolide derivative, under mild conditions. Since a quantitative protection / deprotection method relating to the 9-position hydroxyl group of the lactone ring has been found, the details thereof will be described below with reference to Process Diagram 1. In Process Diagram 1, a lactone ring is shown as an example of the production process. Of 9
A natural 16-membered macrolide antibiotic with position sp 3 carbon is used as a starting material, but when a compound with a carbonyl group at position 9 is used as a starting material, a similar methodology is used to indirectly It is possible to efficiently introduce a methyl group into the tertiary hydroxyl group at the position.

【0020】第一に、式(II)で表された化合物の遊離
水酸基のうち、3"位以外の二つの水酸基、即ち9位及び
2'位の水酸基に置換基を導入して、式(V)で表される
化合物を得る。始めに式(II)(式中、R1は炭素数1〜
3の直鎖のアルキル基であり、R4は炭素数2〜5の直鎖
又は分枝鎖の脂肪族アシル基である)で表される化合物
のラクトン環の9位水酸基を適当な置換基で修飾(或い
は保護)して、式(IV)(式中、R1は炭素数1〜3の直
鎖のアルキル基であり、R4は炭素数2〜5の直鎖又は分
枝鎖の脂肪族アシル基であり、R5は水酸基を修飾(或い
は保護)する置換基である)で表される化合物を得る。
First, among the free hydroxyl groups of the compound represented by the formula (II), two hydroxyl groups other than the 3 "position, that is, the 9 position and
A substituent is introduced into the 2'-position hydroxyl group to obtain a compound represented by the formula (V). First, the formula (II) (in the formula, R 1 is a carbon number of 1 to
3 is a straight-chain alkyl group, and R 4 is a straight-chain or branched-chain aliphatic acyl group having 2 to 5 carbon atoms). Modified (or protected) with formula (IV) (wherein R 1 is a straight chain alkyl group having 1 to 3 carbon atoms, and R 4 is a straight chain or branched chain group having 2 to 5 carbon atoms). A compound represented by an aliphatic acyl group and R 5 is a substituent that modifies (or protects) a hydroxyl group is obtained.

【0021】置換基R5としては、低級脂肪族アシル基
(発酵と工業, 37(12), 1171(1979))は勿論のこと通常
の水酸基の修飾に用いることのできる置換基、例えばメ
トキシメチル基及びエトキシエチル基等でよい。さらに
置換基R5を16員環マクロリド誘導体の水酸基の保護基
として取扱う予定のある場合は、不斉炭素を有するアセ
タール系の置換基、例えば1-エトキシエチル基、テトラ
ヒドロフラニル基或いはテトラヒドロピラニル基等が好
都合である。
As the substituent R 5 , not only a lower aliphatic acyl group (Fermentation and Industry, 37 (12), 1171 (1979)) but also a substituent that can be used for ordinary modification of a hydroxyl group, for example, methoxymethyl is used. Groups and ethoxyethyl groups and the like. Further, when the substituent R 5 is to be treated as a protective group for the hydroxyl group of the 16-membered ring macrolide derivative, an acetal-based substituent having an asymmetric carbon, for example, 1-ethoxyethyl group, tetrahydrofuranyl group or tetrahydropyranyl group Etc. are convenient.

【0022】その一例として、メデマイシン(式(II)
において、R1がエチル基であり、R4がプロピオニル基で
ある化合物)を無水塩化メチレン中ピリジニウム p-ト
ルエンスルホナート(PPTS)の存在下にエチルビニルエ
ーテルと反応させて、化合物(7)(式(IV)におい
て、R1がエチル基であり、R4がプロピオニル基であり、
R5が1-エトキシエチル基である化合物)を収率良く合成
した。なお、当該工程において用いることのできる置換
基の種類及び置換基を導入する際の反応条件はここに記
述したものに限定されることなく、水酸基の保護基とし
て用いられている一般の置換基(Theodora W. Greene;
Peter G. M. Wuts. Protective Groups inOrganic Synt
hesis, 2nd ed., Wiley: New York, 1991)はもとよ
り、保護基として用いることが困難な置換基に関して
も、それらの種類とそれらを導入する反応条件の全てを
包含するものである。
As an example thereof, medemycin (formula (II)
In which R 1 is an ethyl group and R 4 is a propionyl group) is reacted with ethyl vinyl ether in the presence of pyridinium p-toluenesulfonate (PPTS) in anhydrous methylene chloride to give compound (7) (formula In (IV), R 1 is an ethyl group, R 4 is a propionyl group,
A compound in which R 5 is a 1-ethoxyethyl group was synthesized in good yield. The types of substituents that can be used in the step and the reaction conditions when introducing the substituents are not limited to those described here, and general substituents used as protective groups for hydroxyl groups ( Theodora W. Greene;
Peter GM Wuts. Protective Groups in Organic Synt
Hesis , 2nd ed., Wiley: New York, 1991), as well as the substituents that are difficult to use as a protecting group, and include all types and reaction conditions for introducing them.

【0023】ところで不斉炭素を有するアセタール系の
保護基、例えば1-エトキシエチル基等をラクトン環の9
位の水酸基に導入すると、当該置換基の導入されている
間は、誘導体は二種類のジアステレオ異性体の混合物と
して存在する。しかしながらこれらの異性体は分離して
もしなくともよい。又、当該置換基をラクトン環の9位
水酸基の修飾基としてとらえている場合も、これらの異
性体は分離してもしなくともよい。
By the way, an acetal-based protecting group having an asymmetric carbon, such as a 1-ethoxyethyl group, is attached to the lactone ring 9
When introduced into the hydroxyl group at the position, the derivative exists as a mixture of two diastereoisomers while the substituent is introduced. However, these isomers may or may not be separated. Also, when the substituent is regarded as a modifying group for the 9-position hydroxyl group of the lactone ring, these isomers may or may not be separated.

【0024】次いで式(IV)で表される化合物の、マイ
カミノース(アミノ糖)部分である2'位の水酸基をアセ
チル基により保護し、式(V)(式中、R1は炭素数1〜
3の直鎖のアルキル基であり、R4は炭素数2〜5の直鎖
又は分枝鎖の脂肪族アシル基であり、R5は水酸基を修飾
(或いは保護)する置換基である)で表される化合物を
得る。例えば化合物(7)を無水アセトニトリル中無水
酢酸と反応させて化合物(8)(式(V)において、R1
がエチル基であり、R4がプロピオニル基であり、R5が1-
エトキシエチル基である化合物)を定量的に得た。この
時式(V)で表される化合物のうち、R5がアセチル基で
ある化合物は、式(II)で表される化合物より一工程で
調製することが可能である。また、式(V)で表される
化合物は、式(II)で表される化合物のマイカミノース
部分の2'位水酸基を選択的にアセチル化した後に、ラク
トン環9位の水酸基に置換基を導入しても容易に調製す
ることが可能である。
Next, in the compound represented by the formula (IV), the hydroxyl group at the 2'-position which is the mycaminose (amino sugar) moiety is protected by an acetyl group, and the compound represented by the formula (V) (in the formula, R 1 has 1 to 10 carbon atoms
3 is a linear alkyl group, R 4 is a linear or branched aliphatic acyl group having 2 to 5 carbon atoms, and R 5 is a substituent that modifies (or protects) a hydroxyl group. The compound represented is obtained. For example, compound (7) is reacted with acetic anhydride in anhydrous acetonitrile to give compound (8) (in formula (V), R 1
Is an ethyl group, R 4 is a propionyl group, and R 5 is 1-
A compound having an ethoxyethyl group) was quantitatively obtained. At this time, among the compounds represented by the formula (V), the compound in which R 5 is an acetyl group can be prepared from the compound represented by the formula (II) in one step. In addition, the compound represented by the formula (V) is a compound represented by the formula (II), in which the 2'-position hydroxyl group of the mycaminose portion is selectively acetylated, and then a substituent is introduced into the hydroxyl group at the 9-position of the lactone ring. However, it can be easily prepared.

【0025】第二に鍵化合物であるメチルチオメチルエ
ーテル合成中間体の調製法について記す。始めに中性糖
である3"位の3級水酸基にメチルチオメチル基を導入す
る。2級水酸基をカルボニル基に酸化すべく、ジメチル
スルホキシド(DMSO)と無水酢酸を反応させた際に、副
生成物としてメチルチオメチルエーテルが得られること
は1960年代より知られていた(ジャーナル・オブ・アメ
リカン・ケミカル・ソシエチー, 89(10), 2416(196
7))。1970年代中頃には、天然有機化合物の合成におい
てメチルチオメチル基が3級水酸基の保護基として最適
であることも日本の研究グループにより報告されている
(テトラヘドロン・レターズ, 65(1976))。1970年代後
半に入ると、酸化に優先してメチルチオメチル化を進行
させるために反応系中に酢酸を添加することの理論的な
解釈も発表された(オーストラリアン・ジャーナル・オ
ブ・ケミストリー, 31, 1031(1978))。
Secondly, a method for preparing a key compound, a synthetic intermediate of methylthiomethyl ether, will be described. First, a methylthiomethyl group is introduced into the tertiary hydroxyl group at the 3 "position, which is a neutral sugar. When dimethyl sulfoxide (DMSO) is reacted with acetic anhydride to oxidize the secondary hydroxyl group to a carbonyl group, a by-product is formed. It has been known since the 1960s that methyl thiomethyl ether can be obtained as a product (Journal of American Chemical Society, 89 (10), 2416 (196
7)). In the mid-1970s, it was also reported by the Japanese research group that the methylthiomethyl group was the most suitable as a protective group for the tertiary hydroxyl group in the synthesis of natural organic compounds (Tetrahedron Letters, 65 (1976)). In the late 1970s, the theoretical interpretation of adding acetic acid to the reaction system to promote methylthiomethylation over oxidation was also published (Australian Journal of Chemistry, 31 , 1031 (1978)).

【0026】まず当社研究グループの方法(ジャーナル
・オブ・アンチビオチックス, 33(1), 61(1980))に従
い、式(V)で表される化合物の3"位の水酸基をメチル
チオメチル化し、収率60〜70%程度で、式(VI)(式
中、R1は炭素数1〜3の直鎖のアルキル基であり、R4
炭素数2〜5の直鎖又は分枝鎖の脂肪族アシル基であ
り、R5は水酸基を修飾(或いは保護)する置換基であ
る)で表される化合物を合成する。例えば化合物(8)
にDMSOと無水酢酸を反応させて、化合物(9)(式(V
I)においてR1がエチル基であり、R4がプロピオニル基
であり、R5が1-エトキシエチル基である化合物)を合成
した。水酸基へのメチルチオメチル基の導入法に関して
は多くの既知の方法(Theodora W. Greene; Peter G.
M. Wuts. ProtectiveGroups in Organic Synthesis, 2n
d ed., Wiley: New York, 1991)があるので、本発明製
造法はメチルチオメチル基の導入法について限定される
ものではなく、当該導入法に関する全ての既知の方法を
包含する。
First, according to the method of our research group (Journal of Antibiotics, 33 (1), 61 (1980)), the hydroxyl group at the 3 "position of the compound represented by the formula (V) is methylthiomethylated, With a yield of about 60 to 70%, R 1 is a linear alkyl group having 1 to 3 carbon atoms, and R 4 is a linear or branched chain having 2 to 5 carbon atoms. A compound represented by an aliphatic acyl group and R 5 is a substituent that modifies (or protects) a hydroxyl group is synthesized, for example, compound (8)
DMSO is reacted with acetic anhydride to give compound (9) (formula (V
In I), a compound in which R 1 is an ethyl group, R 4 is a propionyl group, and R 5 is a 1-ethoxyethyl group) was synthesized. There are many known methods for introducing a methylthiomethyl group into a hydroxyl group (Theodora W. Greene; Peter G.
M. Wuts. ProtectiveGroups in Organic Synthesis , 2n
ed., Wiley: New York, 1991), the production method of the present invention is not limited to the method for introducing a methylthiomethyl group, and includes all known methods related to the introduction method.

【0027】次いで、式(VI)で表される化合物の2'位
の水酸基に結合していたアセチル基を脱保護し、式(VI
I)(式中、R1は炭素数1〜3の直鎖のアルキル基であ
り、R 4は炭素数2〜5の直鎖又は分枝鎖の脂肪族アシル
基であり、R5は水酸基を修飾(或いは保護)する置換基
である)で表される鍵化合物、即ちメチルチオメチルエ
ーテル合成中間体を定量的に得る。例えば化合物(9)
をメタノール中で反応することにより化合物(10)
(式(VII)において、R1がエチル基であり、R4がプロ
ピオニル基であり、R5が1-エトキシエチル基である化合
物)を得た。
Next, the 2'position of the compound represented by the formula (VI)
The acetyl group bonded to the hydroxyl group of
I) (In the formula, R1Is a linear alkyl group having 1 to 3 carbon atoms
R FourIs a linear or branched aliphatic acyl having 2 to 5 carbon atoms
The base and RFiveIs a substituent that modifies (or protects) the hydroxyl group
Is a key compound represented by
The ether synthetic intermediate is quantitatively obtained. For example, compound (9)
To give compound (10)
(In the formula (VII), R1Is an ethyl group and RFourIs a professional
Is a pionyl group, RFiveIs a 1-ethoxyethyl group
Thing).

【0028】第三に、式(VII)で表される鍵中間体の
中性糖部分である3"位の3級水酸基に導入されたメチル
チオメチル基を選択的に還元して、3"位の3級水酸基が
メチル化された16員環マクロリド誘導体を効率的に合
成する。糖質化学においてメチルチオメチル化された2
級水酸基がラネーニッケルにより還元されメトキシ基に
化学変換されることが報告(カーボハイドレート・リサ
ーチ, 7, 474(1968))されて以来、同様の反応例が紹介
されている(テトラヘドロン・レターズ, 43(1969)、カ
ーボハイドレート・リサーチ, 15, 101(1970))。又比
較的最近では、メチルチオメチル基以外の置換基として
アリールチオメチル基の導入された1級及び2級の水酸
基がラジカル還元等を受け、メトキシ基に化学変換され
るという報告がなされた(ジャーナル・オブ・オーガニ
ック・ケミストリー, 54(25), 5998(1989))。
Thirdly, the methylthiomethyl group introduced into the tertiary hydroxyl group at the 3 "position, which is the neutral sugar moiety of the key intermediate represented by the formula (VII), is selectively reduced to give the 3" position. The 16-membered ring macrolide derivative in which the tertiary hydroxyl group is methylated is efficiently synthesized. 2 methylthiomethylated in carbohydrate chemistry
Since it was reported that the primary hydroxyl group was reduced by Raney nickel and chemically converted to a methoxy group (Carbohydrate Research, 7 , 474 (1968)), a similar reaction example was introduced (Tetrahedron Letters, 43 (1969), Carbohydrate Research, 15 , 101 (1970)). In addition, relatively recently, it was reported that primary and secondary hydroxyl groups having an arylthiomethyl group introduced as a substituent other than the methylthiomethyl group undergo radical reduction or the like and are chemically converted to a methoxy group (Journal・ Of Organic Chemistry, 54 (25), 5998 (1989)).

【0029】以上述べた様に、メチルチオメチル化され
た水酸基をメトキシ基に還元する方法論それ自身は決し
て新しいものではないが、当該還元反応の多くは2級の
水酸基に関してなされたものであった。さらに反応基質
には二重結合や遊離のアルデヒド基等、接触還元に対し
て反応性を示す官能基を有しない場合がほとんどであっ
た。
As described above, the methodology for reducing a methylthiomethylated hydroxyl group to a methoxy group is by no means new, but most of the reduction reaction was carried out with a secondary hydroxyl group. Further, in most cases, the reaction substrate does not have a functional group showing reactivity to catalytic reduction such as a double bond or a free aldehyde group.

【0030】本発明者らは、適度に活性をコントロール
したラネーニッケルを用いて、式(VII)で表される化
合物の二重結合及び遊離のアルデヒド基が還元を受ける
ことなく、メチルチオメチル化された3"位の3級水酸基
をメトキシ基に化学変換し、式(VIII)(式中、R1は炭
素数1〜3の直鎖のアルキル基であり、R4は炭素数2〜
5の直鎖又は分枝鎖の脂肪族アシル基であり、R5は水酸
基を修飾(或いは保護)する置換基である)で表される
化合物を選択的に合成する実質的な調製法を見い出し
た。例えば、化合物(10)をエタノール中、適度に活
性をコントロールしたラネーニッケルとともに室温で短
時間撹拌することにより、選択的に化合物(11)(式
(VIII)中、R1がエチル基であり、R4がプロピオニル基
であり、R5が1-エトキシエチル基である化合物)を合成
した。当該選択的還元反応は、R5がアセタール系以外の
置換基、例えば化合物(1)の如くアセチル基で修飾
(或いは保護)されていた場合にも効率良く進行する
(実施例1参照)。
The present inventors have used Raney nickel with moderately controlled activity to methylthiomethylate the double bond and the free aldehyde group of the compound of formula (VII) without undergoing reduction. By chemically converting the tertiary hydroxyl group at the 3 "-position to a methoxy group, formula (VIII) (wherein R 1 is a linear alkyl group having 1 to 3 carbon atoms, and R 4 is 2 to 2 carbon atoms).
5 is a straight-chain or branched-chain aliphatic acyl group, and R 5 is a substituent that modifies (or protects) the hydroxyl group. It was For example, the compound (10) is selectively stirred with Raney nickel whose activity is appropriately controlled at room temperature in ethanol to selectively give the compound (11) (in the formula (VIII), R 1 is an ethyl group, and R A compound in which 4 is a propionyl group and R 5 is a 1-ethoxyethyl group) was synthesized. The selective reduction reaction efficiently proceeds even when R 5 is modified (or protected) with a substituent other than acetal, for example, an acetyl group like compound (1) (see Example 1).

【0031】当該選択的還元反応においては、ラネーニ
ッケルの活性のコントロール方法、反応溶媒、反応後の
後処理の方法等に関しては、後述した実施例1、4、1
0及び11において記載したが、本発明製造法は、それ
らの反応条件等に限定されるものではなく、それらの修
飾手段もまた本製造法に包含されるものである。
In the selective reduction reaction, the methods for controlling the Raney nickel activity, the reaction solvent, the post-treatment method after the reaction, etc. are described in Examples 1, 4, 1 below.
Although described in 0 and 11, the production method of the present invention is not limited to the reaction conditions and the like, and the modification means thereof is also included in the present production method.

【0032】即ち、ラネーニッケルの活性をコントロー
ルするには、本発明の実施例1において記載したアセト
ンによる方法に限定する必要はなく、酢酸エチルや熱水
を用いて当該コントロールを実施してもよい。或いは反
応系中に窒素原子又は硫黄原子等を含むある種の有機化
合物ないしは無機化合物を添加して、反応の選択性を向
上させることも可能である。一方反応溶媒もまた、エタ
ノールの如く低級アルコールに限定されることはなく、
1,4-ジオキサンの如くエーテル系の有機溶媒を用いて、
当該反応を実施することが可能である。更に反応後の後
処理の方法に関しても、反応生成物を分解させることな
く、それらをラネーニッケルより効率良く抽出が可能で
あるなら、その方法は限定されるものではない。
That is, in order to control the activity of Raney nickel, it is not necessary to limit to the method using acetone described in Example 1 of the present invention, and the control may be performed using ethyl acetate or hot water. Alternatively, it is possible to improve the selectivity of the reaction by adding a certain organic compound or inorganic compound containing a nitrogen atom, a sulfur atom or the like to the reaction system. On the other hand, the reaction solvent is not limited to lower alcohols such as ethanol,
Using an ether-based organic solvent such as 1,4-dioxane,
It is possible to carry out the reaction. Further, the method of post-treatment after the reaction is not limited as long as the reaction products can be extracted more efficiently than Raney nickel without decomposing the reaction products.

【0033】以上の如く調製した式(VIII)で表される
化合物は、それ自身で臨床上重要なグラム陽性菌の発育
を阻止し、優れたin vivo効果を示す。又この時R5があ
る種のアセタール系の置換基、例えば1-エトキシエチル
基、テトラヒドロフラニル基或いはテトラヒドロピラニ
ル基等の場合は、さらにこれらの置換基を収率良く脱保
護することが可能である。
The compound represented by the formula (VIII) prepared as described above, by itself, inhibits the growth of clinically important Gram-positive bacteria and exhibits an excellent in vivo effect. Further, at this time, in the case where R 5 is a certain acetal-based substituent such as 1-ethoxyethyl group, tetrahydrofuranyl group or tetrahydropyranyl group, it is possible to further deprotect these substituents in good yield. Is.

【0034】即ち、式(VIII)で表される化合物のラク
トン環の9位水酸基に導入されている置換基を、その置
換基に相応しい条件(Theodora W. Greene; Peter G.
M. Wuts. Protective Groups in Organic Synthesis, 2
nd ed., Wiley: New York, 1991)を用いて脱保護し、
式(IX)(式中、R1は炭素数1〜3の直鎖のアルキル基
であり、R4は炭素数2〜5の直鎖又は分枝鎖の脂肪族ア
シル基である)で表される化合物を定量的に得る。例え
ば化合物(11)を5%酢酸水溶液:アセトニトリル
(3:1)の混合溶媒で反応させることにより、化合物
(12)(式(IX)において、R1がエチル基であり、R4
がプロピオニル基である化合物)を得た。以上の如く製
造した式(IX)で表される化合物も又、それ自身で臨床
上重要なグラム陽性菌の発育を強く阻止する。
That is, the substituent introduced into the 9-position hydroxyl group of the lactone ring of the compound represented by the formula (VIII) is treated under conditions suitable for the substituent (Theodora W. Greene; Peter G.
M. Wuts. Protective Groups in Organic Synthesis , 2
nd ed., Wiley: New York, 1991)
Formula (IX) (in the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms, and R 4 is a linear or branched aliphatic acyl group having 2 to 5 carbon atoms) The compound obtained is quantitatively obtained. For example, compound (11) is reacted with a mixed solvent of 5% aqueous acetic acid solution: acetonitrile (3: 1) to give compound (12) (in formula (IX), R 1 is an ethyl group, R 4
Was a propionyl group). The compound represented by the formula (IX) produced as described above also strongly inhibits the growth of clinically important Gram-positive bacteria.

【0035】工程図1においては、式(VII)で表され
る化合物より式(IX)で表される化合物を合成する際
は、始めに中性糖部分である3"位のメチルチオメチルエ
ーテルをメトキシ基に還元した後に、ラクトン環の9位
水酸基に結合している置換基を脱保護した。一方、始め
に9位を脱保護した後に3"位の還元を行なった場合も、
式(IX)で表される化合物を製造することが可能であ
る。しかしながら、3"位の当該選択的還元反応における
収率及び選択性は、基質として式(VII)で表される化
合物を用いた場合の方がより優れている。
In the process diagram 1, when the compound represented by the formula (IX) is synthesized from the compound represented by the formula (VII), first, methylthiomethyl ether at the 3 "-position, which is a neutral sugar moiety, is added. After reduction to the methoxy group, the substituent bonded to the hydroxyl group at the 9-position of the lactone ring was deprotected. On the other hand, when the 3'-position was reduced after deprotecting the 9-position first,
It is possible to produce compounds of formula (IX). However, the yield and selectivity in the selective reduction reaction at the 3 "-position are better when the compound represented by the formula (VII) is used as the substrate.

【0036】ところで式(IX)で表される化合物、又は
その塩に対しては、9位又は2'位の水酸基を選択的にア
シル化する公知の方法(発酵と工業, 37(12), 1171(197
9))(実施例23参照)又は希薄な酸の存在下に9位の
水酸基を11位又は13位へアリル転位させる公知の方法
(ケミカル・アンド・ファーマシューチカル・ブレタ
ン, 18(8), 1501(1970)、明治製菓研究年報, 12, 85(19
72)、ジャーナル・オブ・アンチビオチックス, 35(11),
1521(1982))或いは9位の水酸基を選択的に酸化する
公知の方法(ジャーナル・オブ・アンチビオチックス,
24(8), 526(1971))等を実施して、本発明を基軸とした
新規有用物質を造出することが可能である。次に本発明
を実施例によって詳細に記述する。
By the way, for the compound represented by the formula (IX) or a salt thereof, a known method of selectively acylating the hydroxyl group at the 9-position or 2'-position (Fermentation and Industry, 37 (12), 1171 (197
9)) (see Example 23) or a known method for allylic rearrangement of the 9-position hydroxyl group to the 11-position or 13-position in the presence of a dilute acid (Chemical and Pharmaceutical Bretan, 18 (8), 1501 ( 1970), Annual Report of Meiji Seika, 12 , 85 (19)
72), Journal of Antibiotics, 35 (11),
1521 (1982)) or a known method for selectively oxidizing the hydroxyl group at the 9-position (Journal of Antibiotics,
24 (8), 526 (1971)), etc., and a novel useful substance based on the present invention can be produced. The present invention will now be described in detail by way of examples.

【0037】[0037]

【実施例】【Example】

実施例1化合物(2)(式(VIII)において、R1がエチル基で表
され、R4がプロピオニル基で表され、R5がアセチル基で
表される化合物)(特願平5-169418)の製造法 始めにラネーニッケルの活性をコントロールした。即ち
ラネーニッケル 6 mlを各 10 mlの水で2回洗浄した
後、発熱を抑えつつ各 10 mlのアセトンで3回洗浄し活
性を適度に調整した。次いで各 10 mlのエタノールで2
回洗浄し反応に用いることにした。化合物(1)(式
(VII)において、R1がエチル基で表され、R 4がプロピ
オニル基で表され、R5がアセチル基で表される化合物)
(ジャーナル・オブ・アンチビオチックス, 33(1), 61
(1980)) 227 mgをエタノール 20 mlに溶解した後、活
性をコントロールした上記ラネーニッケルを 5.0 mlの
エタノールと共に反応溶液に加えた。これを室温で20
分間激しく撹拌した後、不溶物を濾過し、1%(v/v)の濃
アンモニア水を含むエタノール各 20 mlで2回洗浄し
た。濾液と洗液を合わせ、減圧濃縮して得られた残さ 2
90 mgを分離用TLC(展開系:ベンゼン−アセトン(3:
1))で精製して化合物(2) 79 mgを得た。
 Example 1Compound (2) (in the formula (VIII), R 1 represents an ethyl group.
R 4 is a propionyl group and R 5 is an acetyl group.
Compound represented) (Japanese Patent Application No. 5-169418) First, the activity of Raney nickel was controlled. That is
6 ml of Raney nickel washed twice with 10 ml of water each time
After that, wash with 10 ml of acetone for 3 times while suppressing heat generation.
The sex was adjusted appropriately. Then 2 with each 10 ml ethanol
It was washed twice and used for the reaction. Compound (1) (formula
In (VII), R1Is represented by an ethyl group, R FourIs propi
Represented by an onyl group, RFiveIs a compound represented by an acetyl group)
(Journal of Antibiotics,33(1), 61
(1980)) After dissolving 227 mg in 20 ml of ethanol,
Of Raney Nickel with controlled
It was added to the reaction solution together with ethanol. 20 at room temperature
After stirring vigorously for 1 minute, the insoluble matter was filtered and concentrated to 1% (v / v).
Wash twice with 20 ml each of ethanol containing ammonia water
Was. The filtrate and washings were combined and concentrated under reduced pressure to obtain a residue 2
90 mg of TLC for separation (Development system: benzene-acetone (3:
The compound (2) 79 mg was obtained by purification with 1)).

【0038】実施例2化合物(4)(式(VI)において、R1がメチル基で表さ
れ、R4がイソバレリル基で表され、R5がアセチル基で表
される化合物)の製造法 化合物(3)(式(V)において、R1がメチル基で表さ
れ、R4がイソバレリル基で表され、R5がアセチル基で表
される化合物)(テトラヘドロン・レターズ,609(196
7)) 2.0 gをDMSO 63 mlと無水酢酸 6.3 mlの混合溶液
に溶解した後、 33℃で3日間反応させた。反応液にト
ルエン 2.0 Lを加えた後、水 2.0 Lで4回洗浄した。ト
ルエン層を無水硫酸ナトリウムで乾燥後これを濾過し、
濾液を減圧濃縮して得られた残さ 3.00 gをシリカゲル
カラムクロマトグラフィー(300 g:ヘキサン−酢酸エチ
ル(3:1)→(1:1))で精製して、化合物(4) 1.4 gを得
た。 化合物(4)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4877NO17S (3) マススペクトル (SIMS) : m/z 972 (M+H)+ (4) 比旋光度 : [α]D 24 -85°(c1.0, CHCl3) (5) 融点 : 明瞭な融点を示さず、118〜122℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.25(br d, 2-H), 2.72(dd, 2-H), 5.09(br
d, 3-H), 3.16(br d, 4-H), 3.50(s, 4-OCH3), 3.94(br
d, 5-H), 0.85(br ddd, 7-H), 1.46(br dt, 7-H), 5.0
5(dd, 9-H), 5.56(dd, 10-H), 6.70(dd, 11-H), 6.05(b
r dd, 12-H), 5.85(ddd, 13-H), 2.45(br dt, 14-H),
4.99(ddq, 15-H), 1.26(d, 16-H3), 2.55(br dd, 17-
H), 2.81(br dd, 17-H), 9.63(br s, 18-H), 0.96(d, 1
9-H3), 2.30(s, 3-OCOCH3), 2.00(s, 9-OCOCH3), 4.59
(d, 1'-H), 4.91(dd, 2'-H), 2.68(t, 3'-H), 3.16(t,
4'-H), 3.26(dq, 5'-H), 1.14(d, 6'-H3), 2.00(s, 2'-
OCOCH3), 2.42(s, 3'-N(CH3)2), 4,81(d, 1"-H), 1.68
(dd, 2"-Hax), 1.18(s, 3"-CH3), 4.63(d, 4"-H), 4.56
(dq,5"-H), 1.05(d, 6"-H3), 4.50(d, 3"-OCH 2SCH3),
4.64(d, 3"-OCH 2SCH3), 2.20(s, 3"-OCH2SCH3 ), 0.98
(d, 4"-OCOCH2CH(CH3)2 )
Example 2 Compound (4) (in the formula (VI), R 1 represents a methyl group.
R 4 is an isovaleryl group and R 5 is an acetyl group.
In the compound) of Preparation Compound (3) (formula (V), R 1 is represented by a methyl group, R 4 is represented by an isovaleryl group, a compound R 5 is represented by an acetyl group) (Tetrahedron・ Letters, 609 (196
7)) 2.0 g was dissolved in a mixed solution of 63 ml of DMSO and 6.3 ml of acetic anhydride, and then reacted at 33 ° C for 3 days. After 2.0 L of toluene was added to the reaction solution, it was washed 4 times with 2.0 L of water. The toluene layer was dried over anhydrous sodium sulfate and then filtered,
3.00 g of the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (300 g: hexane-ethyl acetate (3: 1) → (1: 1)) to obtain 1.4 g of compound (4). It was Physicochemical properties of compound (4) (1) Color and shape: colorless solid (2) Molecular formula: C 48 H 77 NO 17 S (3) Mass spectrum (SIMS): m / z 972 (M + H) + (4) ) Specific rotation: [α] D 24 -85 ° (c1.0, CHCl 3 ) (5) Melting point: Melting at 118-122 ° C without showing clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.25 (br d, 2-H), 2.72 (dd, 2-H), 5.09 (br
d, 3-H), 3.16 (br d, 4-H), 3.50 (s, 4-OCH 3 ), 3.94 (br
d, 5-H), 0.85 (br ddd, 7-H), 1.46 (br dt, 7-H), 5.0
5 (dd, 9-H), 5.56 (dd, 10-H), 6.70 (dd, 11-H), 6.05 (b
r dd, 12-H), 5.85 (ddd, 13-H), 2.45 (br dt, 14-H),
4.99 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.55 (br dd, 17-
H), 2.81 (br dd, 17-H), 9.63 (br s, 18-H), 0.96 (d, 1
9-H 3 ), 2.30 (s, 3-OCOCH 3 ), 2.00 (s, 9-OCOCH 3 ), 4.59
(d, 1'-H), 4.91 (dd, 2'-H), 2.68 (t, 3'-H), 3.16 (t,
4'-H), 3.26 (dq, 5'-H), 1.14 (d, 6'-H 3 ), 2.00 (s, 2'-
OCOCH 3 ), 2.42 (s, 3'-N (CH 3 ) 2 ), 4,81 (d, 1 "-H), 1.68
(dd, 2 "-Hax), 1.18 (s, 3" -CH 3 ), 4.63 (d, 4 "-H), 4.56
(dq, 5 "-H), 1.05 (d, 6" -H 3 ), 4.50 (d, 3 "-OC H 2 SCH 3 ),
4.64 (d, 3 "-OC H 2 SCH 3 ), 2.20 (s, 3" -OCH 2 SC H 3 ), 0.98
(d, 4 "-OCOCH 2 CH (C H 3 ) 2 )

【0039】実施例3化合物(5)(式(VII)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5がアセチル基で
表される化合物)の製造法 化合物(4) 1.30 gをメタノール 39 mlに溶解した
後、 33℃で16時間反応させた。反応液を減圧濃縮し
て得られた残さ 1.29 gをシリカゲルカラムクロマトグ
ラフィー(125 g:ヘキサン−酢酸エチル(1:1))で精製
して、化合物(5)964 mgを得た。 化合物(5)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4675NO16S (3) マススペクトル (SIMS) : m/z 930 (M+H)+ (4) 比旋光度 : [α]D 24 -77°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、115〜118℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.27(br d, 2-H), 2.75(dd, 2-H), 5.00(br
d, 3-H), 3.25(br d, 4-H), 3.57(s, 4-OCH3), 3.96(br
d, 5-H), 0.93(br ddd, 7-H), 1.57(br dt, 7-H), 4.9
7(dd, 9-H), 5.57(dd, 10-H), 6.71(dd, 11-H), 6.09(b
r dd, 12-H), 5.86(ddd, 13-H), 2.47(br dt, 14-H),
5.00(ddq, 15-H), 1.27(d, 16-H3), 2.59(br dd, 17-
H), 2.84(br dd, 17-H), 9.66(br s, 18-H), 0.96(d, 1
9-H3), 2.29(s, 3-OCOCH3), 2.01(s, 9-OCOCH3), 4.50
(d, 1'-H), 3.21(dd, 2'-H), 2.42(t, 3'-H), 3.42(t,
4'-H), 3.28(dq, 5'-H), 1.15(d, 6'-H3), 2.58(s, 3'-
N(CH3)2), 4,92(d, 1"-H), 1.74(dd, 2"-Hax), 1.20(s,
3"-CH3), 4.66(d, 4"-H), 4.56(dq, 5"-H), 1.08(d,
6"-H 3), 4.52(d, 3"-OCH 2SCH3), 4.65(d, 3"-OCH 2SC
H3), 2.18(s, 3"-OCH2SCH3 ), 0.98(d, 4"-OCOCH2CH(C
H3)2 )
Example 3Compound (5) (in formula (VII), R 1 represents a methyl group.
R 4 is an isovaleryl group and R 5 is an acetyl group.
Represented compound) 1.30 g of compound (4) was dissolved in 39 ml of methanol
Then, the mixture was reacted at 33 ° C for 16 hours. The reaction solution was concentrated under reduced pressure.
1.29 g of the residue obtained by silica gel column chromatography
Purified with Raffy (125 g: hexane-ethyl acetate (1: 1))
Thus, 964 mg of compound (5) was obtained. Physicochemical properties of compound (5) (1) Color and shape: colorless solid (2) molecular formula: C46H75NO16S (3) Mass spectrum (SIMS): m / z 930 (M + H)+ (4) Specific rotation: [α]D twenty four -77 ° (c1.0, CH3OH) (5) Melting point: No clear melting point at 115-118 ° C
Melting (6)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.27 (br d, 2-H), 2.75 (dd, 2-H), 5.00 (br
d, 3-H), 3.25 (br d, 4-H), 3.57 (s, 4-OCH3), 3.96 (br
 d, 5-H), 0.93 (br ddd, 7-H), 1.57 (br dt, 7-H), 4.9
7 (dd, 9-H), 5.57 (dd, 10-H), 6.71 (dd, 11-H), 6.09 (b
r dd, 12-H), 5.86 (ddd, 13-H), 2.47 (br dt, 14-H),
5.00 (ddq, 15-H), 1.27 (d, 16-H3), 2.59 (br dd, 17-
H), 2.84 (br dd, 17-H), 9.66 (br s, 18-H), 0.96 (d, 1
9-H3), 2.29 (s, 3-OCOCH3), 2.01 (s, 9-OCOCH3), 4.50
(d, 1'-H), 3.21 (dd, 2'-H), 2.42 (t, 3'-H), 3.42 (t,
4'-H), 3.28 (dq, 5'-H), 1.15 (d, 6'-H3), 2.58 (s, 3'-
N (CH3)2), 4,92 (d, 1 "-H), 1.74 (dd, 2" -Hax), 1.20 (s,
 3 "-CH3), 4.66 (d, 4 "-H), 4.56 (dq, 5" -H), 1.08 (d,
6 "-H 3), 4.52 (d, 3 "-OCH 2SCH3), 4.65 (d, 3 "-OCH 2SC
H3), 2.18 (s, 3 "-OCH2SCH 3 ), 0.98 (d, 4 "-OCOCH2CH (C
H 3 ) 2 )

【0040】実施例4化合物(6)(式(VIII)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5がアセチル基で
表される化合物)の製造法 化合物(5) 300 mgをエタノール 7.0 mlに溶解した
後、ラネーニッケル 15mlを実施例1と同様の方法で活
性をコントロールし、 7.5 mlのエタノールと共に上記
溶液に加えた。これを室温で20分間激しく撹拌した
後、不溶物を濾過し、1%(v/v)の濃アンモニア水を含む
エタノール各 30 mlで2回洗浄した。濾液と洗液を合わ
せ、減圧濃縮して得られた残さ 297 mgを分離用TLC(展
開系:トルエン−アセトン(3:1))で精製して化合物
(6) 81 mgを得た。 化合物(6)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4573NO16 (3) マススペクトル (SIMS) : m/z 884 (M+H)+ (4) 比旋光度 : [α]D 26 -74°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、115〜119℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.75(dd, 2-H), 5.12(br d, 3-H), 3.25(br
d, 4-H), 3.57(s, 4-OCH3), 3.96(br d, 5-H), 0.92(br
ddd, 7-H), 1.58(br dt, 7-H), 5.06(dd, 9-H), 5.57
(dd, 10-H), 6.71(dd, 11-H), 6.09(br dd, 12-H), 5.8
6(ddd, 13-H), 4.99(ddq, 15-H), 1.26(d, 16-H3), 2.5
9(br dd, 17-H), 2.84(br dd, 17-H), 9.66(br s, 18-
H), 0.96(d, 19-H3), 2.29(s, 3-OCOCH3), 2.01(s, 9-O
COCH3), 4.51(d, 1'-H), 3.19(dd, 2'-H), 2.42(t, 3'-
H), 3.46(t, 4'-H), 3.29(dq, 5'-H), 1.16(d, 6'-H3),
2.58(s, 3'-N(CH3)2), 4,93(d, 1"-H), 1.67(dd, 2"-H
ax), 1.11(s, 3"-CH3), 4.72(d,4"-H), 5.54(dq, 5"-
H), 1.08(d, 6"-H3), 3.26(s, 3"-OCH3), 0.97(d, 4"-O
COCH2CH(CH3)2 )
Example 4 Compound (6) (in the formula (VIII), R 1 represents a methyl group.
R 4 is an isovaleryl group and R 5 is an acetyl group.
After the preparation the compound (5) 300 mg of the compound) represented in ethanol 7.0 ml, Raney nickel 15ml controlling the activity in the same manner as in Example 1, was added to the solution along with 7.5 ml of ethanol. This was vigorously stirred at room temperature for 20 minutes, the insoluble material was filtered off, and washed twice with 30 ml of ethanol each containing 1% (v / v) concentrated aqueous ammonia. The filtrate and washings were combined and concentrated under reduced pressure to obtain 297 mg of the residue, which was purified by preparative TLC (developing system: toluene-acetone (3: 1)) to obtain 81 mg of compound (6). Physicochemical properties of compound (6) (1) Color and shape: colorless solid (2) Molecular formula: C 45 H 73 NO 16 (3) Mass spectrum (SIMS): m / z 884 (M + H) + (4) Specific rotation: [α] D 26 -74 ° (c1.0, CH 3 OH) (5) Melting point: No melting point, melting at 115-119 ° C (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.75 (dd, 2-H), 5.12 (br d, 3-H), 3.25 (br
d, 4-H), 3.57 (s, 4-OCH 3 ), 3.96 (br d, 5-H), 0.92 (br
ddd, 7-H), 1.58 (br dt, 7-H), 5.06 (dd, 9-H), 5.57
(dd, 10-H), 6.71 (dd, 11-H), 6.09 (br dd, 12-H), 5.8
6 (ddd, 13-H), 4.99 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.5
9 (br dd, 17-H), 2.84 (br dd, 17-H), 9.66 (br s, 18-
H), 0.96 (d, 19-H 3 ), 2.29 (s, 3-OCOCH 3 ), 2.01 (s, 9-O
COCH 3 ), 4.51 (d, 1'-H), 3.19 (dd, 2'-H), 2.42 (t, 3'-
H), 3.46 (t, 4'-H), 3.29 (dq, 5'-H), 1.16 (d, 6'-H 3 ),
2.58 (s, 3'-N (CH 3 ) 2 ), 4,93 (d, 1 "-H), 1.67 (dd, 2" -H
ax), 1.11 (s, 3 "-CH 3 ), 4.72 (d, 4" -H), 5.54 (dq, 5 "-
H), 1.08 (d, 6 "-H 3 ), 3.26 (s, 3" -OCH 3 ), 0.97 (d, 4 "-O
COCH 2 CH (C H 3 ) 2 )

【0041】実施例5化合物(7)(式(IV)において、R1がエチル基で表さ
れ、R4がプロピオニル基で表され、R5が1-エトキシエチ
ル基で表される化合物)の製造法 メデマイシン 20 gを塩化メチレン 600 mlとエチルビニ
ルエーテル 22 mlの混合溶液に溶解した後、PPTS 9.4 g
を加え、室温で16時間反応させた。反応液を飽和炭酸
水素ナトリウム水溶液 2.0 Lに徐々に加え、クロロホル
ム 1.8 Lで抽出した。クロロホルム層を5%硫酸水素カリ
ウム水溶液 2.0 L、飽和炭酸水素ナトリウム水溶液 2.0
L及び飽和塩化ナトリウム水溶液 2.0 Lで順次洗浄し
た。クロロホルム層を無水硫酸ナトリウムで乾燥後これ
を濾過し、濾液を減圧濃縮して得られた残さ 23.0 gを
シリカゲルカラムクロマトグラフィー(1.0 kg:クロロ
ホルム−メタノール(50:1))で精製して、化合物(7)
20 gを得た。 化合物(7)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4575NO16 (3) マススペクトル (EIMS) : m/z 885 (M)+ (4) 比旋光度 : [α]D 21 -61°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、100〜103℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.28(br d, 2-H), 2.73(dd, 2-H), 2.74(dd,
2-H), 5.13(br d, 3-H), 3.24(br d, 4-H), 3.53(s, 4
-OCH3), 3.87(br d, 5-H), 1.44(br dt, 7-H), 1.90(m,
8-H), 3.78(dd, 9-H), 3.92(dd, 9-H), 5.47(dd, 10-
H), 5.56(dd, 10-H), 6.57(dd, 11-H), 6.61(dd, 11-
H), 6.09(br dd, 12-H), 5.78(br ddd, 13-H), 5.82(br
ddd, 13-H), 2.15(br dt, 14-H), 5.02(ddq, 15-H),
2.82(br dd, 17-H), 2.83(br dd, 17-H),9.64(br s, 18
-H), 9.65(br s, 18-H), 0.99(d, 19-H3), 1.00(d, 19-
H3), 2.63(br dq, 3-OCOCH 2CH3), 4.64(q, 9-OCH(OCH2C
H3)CH3), 4.66(q, 9-OCH(OCH2CH3)CH3), 3.44(dq, 9-OC
H(OCH 2CH3)CH3), 3.63(dq, 9-OCH(OCH 2CH3)CH3), 4.41
(d,1'-H), 2.51(s, 3'-N(CH3)2), 5.07(d, 1"-H), 1.85
(dd, 2"-Hax), 2.01(d, 2"-Heq), 1.12(s, 3"-CH3), 4.
62(d, 4"-H), 4.46(dq, 5"-H), 1.13(d, 6"-H3), 2.44
(apparent q, 4"-OCOCH 2CH3), 2.46(ap. q, 4"-OCOCH 2C
H3), 1.18(t, 4"-OCOCH2CH3 )
Example 5 Compound (7) (in the formula (IV), R 1 represents an ethyl group.
R 4 is represented by a propionyl group, and R 5 is 1-ethoxyethyl.
The compound represented by the formula (1) is dissolved in a mixed solution of 600 ml of methylene chloride and 22 ml of ethyl vinyl ether, and then 9.4 g of PPTS is added.
Was added, and the mixture was reacted at room temperature for 16 hours. The reaction mixture was gradually added to 2.0 L of saturated aqueous sodium hydrogen carbonate solution, and extracted with 1.8 L of chloroform. Chloroform layer was 5% potassium hydrogen sulfate aqueous solution 2.0 L, saturated sodium hydrogen carbonate aqueous solution 2.0
It was washed successively with L and 2.0 L of a saturated sodium chloride aqueous solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a residue (23.0 g), which was purified by silica gel column chromatography (1.0 kg: chloroform-methanol (50: 1)) to give a compound. (7)
I got 20 g. Physicochemical properties of compound (7) (1) Color and shape: Colorless solid (2) Molecular formula: C 45 H 75 NO 16 (3) Mass spectrum (EIMS): m / z 885 (M) + (4) Specific rotation Degree: [α] D 21 -61 ° (c1.0, CH 3 OH) (5) Melting point: Melting at 100 to 103 ° C without showing a clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.28 (br d, 2-H), 2.73 (dd, 2-H), 2.74 (dd,
2-H), 5.13 (br d, 3-H), 3.24 (br d, 4-H), 3.53 (s, 4
-OCH 3 ), 3.87 (br d, 5-H), 1.44 (br dt, 7-H), 1.90 (m,
8-H), 3.78 (dd, 9-H), 3.92 (dd, 9-H), 5.47 (dd, 10-
H), 5.56 (dd, 10-H), 6.57 (dd, 11-H), 6.61 (dd, 11-
H), 6.09 (br dd, 12-H), 5.78 (br ddd, 13-H), 5.82 (br
ddd, 13-H), 2.15 (br dt, 14-H), 5.02 (ddq, 15-H),
2.82 (br dd, 17-H), 2.83 (br dd, 17-H), 9.64 (br s, 18
-H), 9.65 (br s, 18-H), 0.99 (d, 19-H 3 ), 1.00 (d, 19-
H 3 ), 2.63 (br dq, 3-OCOC H 2 CH 3 ), 4.64 (q, 9-OC H (OCH 2 C
H 3 ) CH 3 ), 4.66 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 3.44 (dq, 9-OC
H (OC H 2 CH 3 ) CH 3 ), 3.63 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 4.41
(d, 1'-H), 2.51 (s, 3'-N (CH 3 ) 2 ), 5.07 (d, 1 "-H), 1.85
(dd, 2 "-Hax), 2.01 (d, 2" -Heq), 1.12 (s, 3 "-CH 3 ), 4.
62 (d, 4 "-H), 4.46 (dq, 5" -H), 1.13 (d, 6 "-H 3 ), 2.44
(apparent q, 4 "-OCOC H 2 CH 3 ), 2.46 (ap. q, 4" -OCOC H 2 C
H 3 ), 1.18 (t, 4 "-OCOCH 2 C H 3 )

【0042】実施例6化合物(8)(式(V)において、R1がエチル基で表さ
れ、R4がプロピオニル基で表され、R5が1-エトキシエチ
ル基で表される化合物)の製造法 化合物(7) 12 gをアセトニトリル 370 mlに溶解した
後、無水酢酸 2.7 mlを加え40℃で16時間反応させ
た。1規定アンモニア水溶液 42 mlを滴下し、室温で1
0分間放置した。反応液を減圧濃縮して得られた残さを
クロロホルム 1.0Lに溶解し、飽和炭酸水素ナトリウム
水溶液 1.0 Lおよび飽和塩化ナトリウム水溶液 1.2 Lで
順次洗浄した。クロロホルム層を無水硫酸ナトリウムで
乾燥後これを濾過し、濾液を減圧濃縮して、化合物
(8)13 gを得た。 化合物(8)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4777NO17 (3) マススペクトル (SIMS) : m/z 928 (M+H)+ (4) 比旋光度 : [α]D 21 -64°(c1.0, CHCl3) (5) 融点 : 明瞭な融点を示さず、104〜107℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.24(br d, 2-H), 2.70(dd, 2-H), 5.11(br
d, 3-H), 3.17(br d, 4-H), 3.47(s, 4-OCH3), 3.89(br
d, 5-H), 1.42(br t, 7-H), 3.75(dd, 9-H), 3.88(dd,
9-H), 5.45(dd, 10-H), 5.54(dd, 10-H), 6.57(dd, 11
-H), 6.61(dd, 11-H), 6.05(br dd, 12-H),5.79(ddd, 1
3-H), 5.83(ddd, 13-H), 2.15(br dt, 14-H), 2.26(br
dd, 17-H),2.81(br dd, 17-H), 9.62(br s, 18-H), 9.6
3(br s, 18-H), 0.98(d, 19-H3),0.99(d, 19-H3), 2.65
(dq, 3-OCOCH 2CH3), 4.64(q, 9-OCH(OCH2CH3)CH3), 4.6
5(q, 9-OCH(OCH2CH3)CH3), 3.35(dq, 9-OCH(OCH 2CH3)CH
3), 3.43(dq, 9-OCH(OCH 2CH3)CH3), 3.49(dq, 9-OCH(OC
H 2CH3)CH3), 3.62(dq, 9-OCH(OCH 2CH3)CH3), 4.61(d,
1'-H), 4.98(dd, 2'-H), 2.02(s, 2'-OCOCH3), 2.41(s,
3'-N(CH3)2), 5.06(d, 1"-H), 1.84(dd, 2"-Hax), 2.0
0(d, 2"-Heq), 1.12(br s, 3"-CH3), 4.62(d,4"-H), 4.
37(dq, 5"-H), 2.43(apparent q, 4"-OCOCH 2CH3), 2.44
(apparent q,4"-OCOCH 2CH3), 1.18(t, 4"-OCOCH2CH3 )
Example 6 Compound (8) (in the formula (V), R 1 represents an ethyl group.
R 4 is represented by a propionyl group, and R 5 is 1-ethoxyethyl.
The compound (7) (12 g) was dissolved in acetonitrile (370 ml), acetic anhydride (2.7 ml) was added, and the mixture was reacted at 40 ° C. for 16 hours. 42 ml of 1N aqueous ammonia solution was added dropwise, and 1 at room temperature
It was left for 0 minutes. The reaction solution was concentrated under reduced pressure, the residue obtained was dissolved in 1.0 L of chloroform, and washed successively with 1.0 L of saturated aqueous sodium hydrogen carbonate solution and 1.2 L of saturated aqueous sodium chloride solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 13 g of compound (8). Physicochemical properties of compound (8) (1) Color and shape: colorless solid (2) Molecular formula: C 47 H 77 NO 17 (3) Mass spectrum (SIMS): m / z 928 (M + H) + (4) Specific rotation: [α] D 21 -64 ° (c1.0, CHCl 3 ) (5) Melting point: Melting at 104-107 ° C without showing clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.24 (br d, 2-H), 2.70 (dd, 2-H), 5.11 (br
d, 3-H), 3.17 (br d, 4-H), 3.47 (s, 4-OCH 3 ), 3.89 (br
d, 5-H), 1.42 (br t, 7-H), 3.75 (dd, 9-H), 3.88 (dd,
9-H), 5.45 (dd, 10-H), 5.54 (dd, 10-H), 6.57 (dd, 11
-H), 6.61 (dd, 11-H), 6.05 (br dd, 12-H), 5.79 (ddd, 1
3-H), 5.83 (ddd, 13-H), 2.15 (br dt, 14-H), 2.26 (br
dd, 17-H), 2.81 (br dd, 17-H), 9.62 (br s, 18-H), 9.6
3 (br s, 18-H), 0.98 (d, 19-H 3 ), 0.99 (d, 19-H 3 ), 2.65
(dq, 3-OCOC H 2 CH 3 ), 4.64 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 4.6
5 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 3.35 (dq, 9-OCH (OC H 2 CH 3 ) CH
3 ), 3.43 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 3.49 (dq, 9-OCH (OC
H 2 CH 3 ) CH 3 ), 3.62 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 4.61 (d,
1'-H), 4.98 (dd, 2'-H), 2.02 (s, 2'-OCOCH 3 ), 2.41 (s,
3'-N (CH 3 ) 2 ), 5.06 (d, 1 "-H), 1.84 (dd, 2" -Hax), 2.0
0 (d, 2 "-Heq), 1.12 (br s, 3" -CH 3 ), 4.62 (d, 4 "-H), 4.
37 (dq, 5 "-H), 2.43 (apparent q, 4" -OCOC H 2 CH 3 ), 2.44
(apparent q, 4 "-OCOC H 2 CH 3 ), 1.18 (t, 4" -OCOCH 2 C H 3 )

【0043】実施例7化合物(9H)(式(VI)において、R1がエチル基で表
され、R4がプロピオニル基で表され、R5が1-エトキシエ
チル基で表される化合物のうち後述した展開系における
TLCにおいてRf値の大きい方の異性体)及び化合物(9
L)(式(VI)において、R1がエチル基で表され、R4
プロピオニル基で表され、R5が1-エトキシエチル基で表
される化合物のうち同Rf値の小さい方の異性体)の製造
化合物(8) 305 mgをDMSO 9.1 mlと無水酢酸 0.91 ml
の混合溶液に溶解した後、30℃で16時間反応させた。
反応液をトルエン 60 mlに徐々に加え、水 60mlで3回
洗浄した。トルエン層を無水硫酸ナトリウムで乾燥後こ
れを濾過し、濾液を減圧濃縮した。得られた残さ 300 m
gをシリカゲルクロマトグラフィー(30g:ヘキサン−酢
酸エチル(1:1))で精製して、化合物(9) 195 mgを得
た。このうち 106 mgを分離用TLC(展開系:ヘキサン−
酢酸エチル(1:1))で再精製し、化合物(9H) 56 mg
及び化合物(9L) 39 mgを得た。 化合物(9H)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4981NO17S (3) マススペクトル (FDMS) : m/z 988 (M+H)+ (4) TLCにおけるRf値 : 0.50(展開系:ヘキサ
ン−酢酸エチル(1:1)) (5) 比旋光度 : [α]D 19 -71°(c1.0, CHCl3) (6) 明瞭な融点を示さず、94〜96℃付近で熔融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.24(br d, 2-H), 2.72(dd, 2-H), 5.11(br
d, 3-H), 3.17(br d, 4-H), 3.49(s, 4-OCH3), 3.87(br
d, 5-H), 0.85(br dt, 7-H), 1.41(br dt, 7-H), 1.87
(m, 8-H), 3.88(dd, 9-H), 5.45(dd, 10-H), 6.61(dd,
11-H), 6.06(br dd, 12-H), 5.82(ddd, 13-H), 2.15(d
t, 14-H), 4.99(ddq, 15-H), 1.26(d, 16-H3), 2.83(br
dd, 17-H),9.62(br s, 18-H), 0.98(d, 19-H3), 2.50
(dq, 3-OCOCH 2CH3), 2.65(dq, 3-OCOCH 2CH3), 1.21(t,
3-OCOCH2CH3 ), 3.42(dq, 9-OCH(OCH 2CH3)CH3), 3.50(d
q, 9-OCH(OCH 2CH3)CH3), 1.14(t, 9-OCH(OCH2CH3 )CH3),
1.22(d, 9-OCH(OCH2CH3)CH3 ),4.60(d, 1'-H), 4.92(d
d, 2'-H), 2.68(t, 3'-H), 3.16(t, 4'-H), 3.26(dq,
5'-H), 1.14(d, 6'-H3), 2.01(s, 2'-OCOCH3), 2.43(s,
3'-N(CH3)2), 4.81(d, 1"-H), 1.68(dd, 2"-Hax), 2.2
5(d, 2"-Heq), 1.17(s, 3"-CH3), 4.56(dq, 5"-H),1.05
(d, 6"-H3), 4.51(d, 3"-OCH 2SCH3), 4.64, 4.65(2×d,
4"-H, 3"-OCH 2SCH 3), 2.20(s, 3"-OCH2SCH3 ), 2.42(q,
4"-OCOCH2 CH3), 1.18(t, 4"-OCOCH2CH3 ) 化合物(9L)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4981NO17S (3) マススペクトル (FDMS) : m/z 988 (M+H)+ (4) TLCにおけるRf値 : 0.46(展開系:ヘキサ
ン−酢酸エチル(1:1)) (5) 比旋光度 : [α]D 19 -87°(c1.0, CHCl3) (6) 明瞭な融点を示さず、90〜94℃付近で熔融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.25(br d, 2-H), 2.72(dd, 2-H), 5.11(br
d, 3-H), 3.18(br d, 4-H), 3.49(s, 4-OCH3), 3.87(br
d, 5-H), 0.87(br dt, 7-H), 1.43(br dt, 7-H), 1.86
(m, 8-H), 3.74(dd, 9-H), 5.54(dd, 10-H), 6.58 (dd,
11-H), 6.06(br dd, 12-H), 5.80(ddd, 13-H), 2.15(d
t, 14-H), 5.00(ddq, 15-H), 1.26(d, 16-H3), 2.84(br
dd, 17-H),9.63(br s, 18-H), 0.98(d, 19-H3), 2.52
(dq, 3-OCOCH 2CH3), 2.65(dq, 3-OCOCH 2CH3), 1.23(t,
3-OCOCH2CH3 ), 4.65(q, 9-OCH(OCH2CH3)CH3), 3.35(dq,
9-OCH(OCH 2CH3)CH3), 3.63(dq, 9-OCH(OCH 2CH3)CH3),
1.14(t, 9-OCH(OCH2CH3 )CH3),1.25(d, 9-OCH(OCH2CH3)C
H3 ), 4.60(d, 1'-H), 4.92(dd, 2'-H), 2.68(t, 3'-H),
3.16(t, 4'-H), 3.26(dq, 5'-H), 1.14(d, 6'-H3), 2.
01(s, 2'-OCOCH3), 2.43(s, 3'-N(CH3)2), 4.81(d, 1"-
H), 1.69(dd, 2"-Hax), 2.26(d, 2"-Heq), 1.17(s, 3"-
CH3), 4.57(dq, 5"-H), 1.05(d, 6"-H3), 4.51(d, 3"-O
CH 2SCH3), 4.64, 4.65(2×d, 4"-H, 3"-OCH 2SCH3), 2.2
0(s, 3"-OCH2SCH3 ), 2.42(q, 4"-OCOCH2 CH3), 1.18(t,
4"-OCOCH2CH3 )
Example 7Compound (9H) (in formula (VI), R 1 represents an ethyl group.
R 4 is a propionyl group and R 5 is 1-ethoxyethyl.
Among the compounds represented by the chill group, in the development system described later
The isomer with the higher Rf value in TLC) and the compound (9
L) (in the formula (VI), R 1 is an ethyl group and R 4 is
It is represented by a propionyl group and R 5 is represented by a 1-ethoxyethyl group.
Isomer of the same compound with the smaller Rf value)
Law Compound (8) 305 mg was added to DMSO 9.1 ml and acetic anhydride 0.91 ml.
After being dissolved in the mixed solution of, the reaction was carried out at 30 ° C. for 16 hours.
The reaction solution was gradually added to 60 ml of toluene, and 60 ml of water was added 3 times.
Washed. After drying the toluene layer with anhydrous sodium sulfate,
It was filtered and the filtrate was concentrated under reduced pressure. Residue obtained 300 m
silica gel chromatography (30 g: hexane-vinegar)
Ethyl acetate (1: 1)) to obtain 195 mg of compound (9)
Was. Of this, 106 mg was used for separation TLC (Development system: Hexane-
Repurified with ethyl acetate (1: 1)), compound (9H) 56 mg
And 39 mg of compounds (9L) were obtained. Physicochemical properties of compound (9H) (1) Color and shape: Colorless solid (2) Molecular formula: C49H81NO17S (3) Mass spectrum (FDMS): m / z 988 (M + H)+ (4) Rf value in TLC: 0.50 (expansion system: hexa
-Ethyl acetate (1: 1)) (5) Specific rotation: [α]D 19 -71 ° (c1.0, CHCl3(6) Melting at around 94-96 ℃ without showing clear melting point (7)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.24 (br d, 2-H), 2.72 (dd, 2-H), 5.11 (br
d, 3-H), 3.17 (br d, 4-H), 3.49 (s, 4-OCH3), 3.87 (br
 d, 5-H), 0.85 (br dt, 7-H), 1.41 (br dt, 7-H), 1.87
(m, 8-H), 3.88 (dd, 9-H), 5.45 (dd, 10-H), 6.61 (dd,
11-H), 6.06 (br dd, 12-H), 5.82 (ddd, 13-H), 2.15 (d
t, 14-H), 4.99 (ddq, 15-H), 1.26 (d, 16-H3), 2.83 (br
 dd, 17-H), 9.62 (br s, 18-H), 0.98 (d, 19-H3), 2.50
(dq, 3-OCOCH 2CH3), 2.65 (dq, 3-OCOCH 2CH3), 1.21 (t,
3-OCOCH2CH 3 ), 3.42 (dq, 9-OCH (OCH 2CH3) CH3), 3.50 (d
q, 9-OCH (OCH 2CH3) CH3), 1.14 (t, 9-OCH (OCH2CH 3 ) CH3),
 1.22 (d, 9-OCH (OCH2CH3) CH 3 ), 4.60 (d, 1'-H), 4.92 (d
d, 2'-H), 2.68 (t, 3'-H), 3.16 (t, 4'-H), 3.26 (dq,
5'-H), 1.14 (d, 6'-H3), 2.01 (s, 2'-OCOCH3), 2.43 (s,
 3'-N (CH3)2), 4.81 (d, 1 "-H), 1.68 (dd, 2" -Hax), 2.2
5 (d, 2 "-Heq), 1.17 (s, 3" -CH3), 4.56 (dq, 5 "-H), 1.05
(d, 6 "-H3), 4.51 (d, 3 "-OCH 2SCH3), 4.64, 4.65 (2 × d,
 4 "-H, 3" -OCH 2SCH 3), 2.20 (s, 3 "-OCH2SCH 3 ), 2.42 (q,
 4 "-OCOCH 2 CH3), 1.18 (t, 4 "-OCOCH2CH 3 ) Physicochemical properties of compound (9L) (1) Color and shape: Colorless solid (2) Molecular formula: C49H81NO17S (3) Mass spectrum (FDMS): m / z 988 (M + H)+ (4) Rf value in TLC: 0.46 (expansion system: hexa
-Ethyl acetate (1: 1)) (5) Specific rotation: [α]D 19 -87 ° (c1.0, CHCl3) (6) Melting around 90-94 ℃ without showing clear melting point (7)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.25 (br d, 2-H), 2.72 (dd, 2-H), 5.11 (br
d, 3-H), 3.18 (br d, 4-H), 3.49 (s, 4-OCH3), 3.87 (br
 d, 5-H), 0.87 (br dt, 7-H), 1.43 (br dt, 7-H), 1.86
(m, 8-H), 3.74 (dd, 9-H), 5.54 (dd, 10-H), 6.58 (dd,
 11-H), 6.06 (br dd, 12-H), 5.80 (ddd, 13-H), 2.15 (d
t, 14-H), 5.00 (ddq, 15-H), 1.26 (d, 16-H)3), 2.84 (br
 dd, 17-H), 9.63 (br s, 18-H), 0.98 (d, 19-H3), 2.52
(dq, 3-OCOCH 2CH3), 2.65 (dq, 3-OCOCH 2CH3), 1.23 (t,
3-OCOCH2CH 3 ), 4.65 (q, 9-OCH(OCH2CH3) CH3), 3.35 (dq,
 9-OCH (OCH 2CH3) CH3), 3.63 (dq, 9-OCH (OCH 2CH3) CH3),
1.14 (t, 9-OCH (OCH2CH 3 ) CH3), 1.25 (d, 9-OCH (OCH2CH3) C
H 3 ), 4.60 (d, 1'-H), 4.92 (dd, 2'-H), 2.68 (t, 3'-H),
 3.16 (t, 4'-H), 3.26 (dq, 5'-H), 1.14 (d, 6'-H3), 2.
01 (s, 2'-OCOCH3), 2.43 (s, 3'-N (CH3)2), 4.81 (d, 1 "-
H), 1.69 (dd, 2 "-Hax), 2.26 (d, 2" -Heq), 1.17 (s, 3 "-
CH3), 4.57 (dq, 5 "-H), 1.05 (d, 6" -H3), 4.51 (d, 3 "-O
CH 2SCH3), 4.64, 4.65 (2 × d, 4 "-H, 3" -OCH 2SCH3), 2.2
0 (s, 3 "-OCH2SCH 3 ), 2.42 (q, 4 "-OCOCH 2 CH3), 1.18 (t,
4 "-OCOCH2CH 3 )

【0044】実施例8化合物(10H)(式(VII)において、R1がエチル基
で表され、R4がプロピオニル基で表され、R5が1-エトキ
シエチル基で表される化合物のうち化合物(9H)より
誘導される異性体)の製造法 化合物(9H) 50 mgをメタノール 1.5 mlに溶解した
後、30℃で16時間反応させた。反応液を減圧濃縮し、
得られた残さ 47 mgを分離用TLC(展開系:ヘキサン−
酢酸エチル(1:1))で精製し、化合物(10H) 36 mg
を得た。 化合物(10H)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4779NO16S (3) マススペクトル (SIMS) : m/z 946 (M+H)+ (4) TLCにおけるRf値 : 0.24(展開系:ヘキサ
ン−酢酸エチル(1:1)) (5) 比旋光度 : [α]D 19 -55°(c1.0, CH3OH) (6) 融点 : 明瞭な融点を示さず、95〜98℃付近
で熔融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 5.13(br
d, 3-H), 3.26(br d, 4-H), 3.57(s, 4-OCH3), 3.88(br
d, 5-H), 0.93(br ddd, 7-H), 1.53(br dt, 7-H), 1.8
9(m, 8-H), 3.90(dd, 9-H), 5.46(dd, 10-H), 6.62(dd,
11-H), 6.10(br dd, 12-H), 5.83(ddd, 13-H), 5.01(d
dq, 15-H), 2.85(br dd, 17-H), 9.63(br s, 18-H), 0.
98(d, 19-H3), 2.51(dq, 3-OCOCH 2CH3), 2.64(dq, 3-OC
OCH 2CH3), 4.64(q, 9-OCH(OCH2CH3)CH3), 3.43(dq, 9-O
CH(OCH 2CH3)CH3), 3.50(dq, 9-OCH(OCH 2CH3)CH3), 4.51
(d, 1'-H), 3.41(t, 4'-H), 3.28(dq, 5'-H), 2.58(s,
3'-N(CH3)2), 4.92(d, 1"-H),1.75(dd, 2"-Hax), 2.28
(d, 2"-Heq), 4.56(dq, 5"-H), 1.08(d, 6"-H3), 4.52
(d, 3"-OCH 2SCH3), 4.65, 4.66(2×d, 4"-H, 3"-OCH 2SC
H3), 2.19(s, 3"-OCH2SCH3 ), 2.42(q, 4"-OCOCH2 CH3)
Example 8 Compound (10H) (in the formula (VII), R 1 is an ethyl group
, R 4 is a propionyl group, and R 5 is 1-ethoxy
From compounds (9H) among compounds represented by cyethyl group
Method for producing derivatized isomer 50 mg of the compound (9H) was dissolved in 1.5 ml of methanol and then reacted at 30 ° C. for 16 hours. The reaction solution is concentrated under reduced pressure,
The obtained residue (47 mg) was used for separation TLC (development system: hexane-
Purified with ethyl acetate (1: 1)), compound (10H) 36 mg
I got Physicochemical properties of compound (10H) (1) Color and shape: colorless solid (2) Molecular formula: C 47 H 79 NO 16 S (3) Mass spectrum (SIMS): m / z 946 (M + H) + (4 ) Rf value in TLC: 0.24 (Development system: Hexane-ethyl acetate (1: 1)) (5) Specific rotation: [α] D 19 -55 ° (c1.0, CH 3 OH) (6) Melting point: Melts in the vicinity of 95-98 ℃ without showing clear melting point (7) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 5.13 (br
d, 3-H), 3.26 (br d, 4-H), 3.57 (s, 4-OCH 3 ), 3.88 (br
d, 5-H), 0.93 (br ddd, 7-H), 1.53 (br dt, 7-H), 1.8
9 (m, 8-H), 3.90 (dd, 9-H), 5.46 (dd, 10-H), 6.62 (dd,
11-H), 6.10 (br dd, 12-H), 5.83 (ddd, 13-H), 5.01 (d
dq, 15-H), 2.85 (br dd, 17-H), 9.63 (br s, 18-H), 0.
98 (d, 19-H 3 ), 2.51 (dq, 3-OCOC H 2 CH 3 ), 2.64 (dq, 3-OC
OC H 2 CH 3 ), 4.64 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 3.43 (dq, 9-O
CH (OC H 2 CH 3 ) CH 3 ), 3.50 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 4.51
(d, 1'-H), 3.41 (t, 4'-H), 3.28 (dq, 5'-H), 2.58 (s,
3'-N (CH 3) 2 ), 4.92 (d, 1 "-H), 1.75 (dd, 2" -Hax), 2.28
(d, 2 "-Heq), 4.56 (dq, 5" -H), 1.08 (d, 6 "-H 3 ), 4.52
(d, 3 "-OC H 2 SCH 3 ), 4.65, 4.66 (2 × d, 4" -H, 3 "-OC H 2 SC
H 3 ), 2.19 (s, 3 "-OCH 2 SC H 3 ), 2.42 (q, 4" -OCOC H 2 CH 3 )

【0045】実施例9化合物(10L)(式(VII)において、R1がエチル基
で表され、R4がプロピオニル基で表され、R5が1-エトキ
シエチル基で表される化合物のうち化合物(9L)より
誘導される異性体)の製造法 化合物(9L) 230 mgをメタノール 6.8 mlに溶解した
後、30℃で16時間反応させた。反応液を減圧濃縮し、
得られた残さ 204 mgを分離用TLC(展開系:ヘキサン−
酢酸エチル(1:1))で精製し、化合物(10L) 150 mg
を得た。 化合物(10L)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4779NO16S (3) マススペクトル (SIMS) : m/z 946 (M+H)+ (4) TLCにおけるRf値 : 0.16(展開系:ヘキサ
ン−酢酸エチル(1:1)) (5) 比旋光度 : [α]D 19 -73°(c1.0, CH3OH) (6) 融点 : 明瞭な融点を示さず、91〜93℃で熔
融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 5.13(br
d, 3-H), 3.26(br d, 4-H), 3.57(s, 4-OCH3), 3.88(br
d, 5-H), 0.94(br ddd, 7-H), 1.53(br dt, 7-H), 1.8
8(m, 8-H), 3.76(dd, 9-H), 5.55(dd, 10-H), 6.59 (d
d, 11-H), 6.09(br dd, 12-H), 5.80(ddd, 13-H), 5.02
(ddq, 15-H), 2.25(br dd, 17-H), 2.85(br dd, 17-H),
9.64(br s,18-H), 2.52(dq, 3-OCOCH 2CH3), 2.65(dq,
3-OCOCH 2CH3), 3.36(dq, 9-OCH(OCH 2CH3)CH3), 3.63(d
q, 9-OCH(OCH 2CH3)CH3), 4.51(d, 1'-H), 3.41(t, 4'-
H), 3.28(dq, 5'-H), 2.59(s, 3'-N(CH3)2), 4.92(d,
1"-H), 1.75(dd, 2"-Hax), 2.28(d, 2"-Heq), 4.56(dq,
5"-H), 1.08(d, 6"-H3), 4.52(d, 3"-OCH 2SCH3), 4.6
5,4.66(2×d, 4"-H, 3"-OCH 2SCH3), 2.19(s, 3"-OCH2SC
H3 ), 2.42(q, 4"-OCOCH2 CH 3)
Example 9Compound (10 L) (in formula (VII), R 1 is an ethyl group
, R 4 is a propionyl group, and R 5 is 1-ethoxy
From compounds (9L) among compounds represented by cyethyl group
Derived isomer) production method 230 mg of the compound (9 L) was dissolved in 6.8 ml of methanol.
Then, the mixture was reacted at 30 ° C. for 16 hours. The reaction solution is concentrated under reduced pressure,
The obtained residue, 204 mg, was used for separation TLC (development system: hexane-
Purified with ethyl acetate (1: 1)), compound (10 L) 150 mg
Got Physicochemical properties of compound (10 L) (1) Color and shape: Colorless solid (2) Molecular formula: C47H79NO16S (3) Mass spectrum (SIMS): m / z 946 (M + H)+ (4) Rf value in TLC: 0.16 (expansion system: hexa
-Ethyl acetate (1: 1)) (5) Specific rotation: [α]D 19 -73 ° (c1.0, CH3OH) (6) Melting point: No melting point, melting at 91-93 ° C
Melt (7)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 5.13 (br
d, 3-H), 3.26 (br d, 4-H), 3.57 (s, 4-OCH3), 3.88 (br
 d, 5-H), 0.94 (br ddd, 7-H), 1.53 (br dt, 7-H), 1.8
8 (m, 8-H), 3.76 (dd, 9-H), 5.55 (dd, 10-H), 6.59 (d
d, 11-H), 6.09 (br dd, 12-H), 5.80 (ddd, 13-H), 5.02
(ddq, 15-H), 2.25 (br dd, 17-H), 2.85 (br dd, 17-H),
 9.64 (br s, 18-H), 2.52 (dq, 3-OCOCH 2CH3), 2.65 (dq,
3-OCOCH 2CH3), 3.36 (dq, 9-OCH (OCH 2CH3) CH3), 3.63 (d
q, 9-OCH (OCH 2CH3) CH3), 4.51 (d, 1'-H), 3.41 (t, 4'-
H), 3.28 (dq, 5'-H), 2.59 (s, 3'-N (CH3)2), 4.92 (d,
1 "-H), 1.75 (dd, 2" -Hax), 2.28 (d, 2 "-Heq), 4.56 (dq,
 5 "-H), 1.08 (d, 6" -H3), 4.52 (d, 3 "-OCH 2SCH3), 4.6
5,4.66 (2 × d, 4 "-H, 3" -OCH 2SCH3), 2.19 (s, 3 "-OCH2SC
H 3 ), 2.42 (q, 4 "-OCOCH 2 CH 3)

【0046】実施例10化合物(11H)(式(VIII)において、R1がエチル基
で表され、R4がプロピオニル基で表され、R5が1-エトキ
シエチル基で表される化合物のうち化合物(10H)よ
り誘導される異性体)の製造法 化合物(10H) 30 mgをエタノール 0.35 mlに溶解し
た後、ラネーニッケル0.75 mlを実施例1と同様の方法
で活性をコントロールし、 0.40 mlのエタノールと共に
上記溶液に加えた。これを室温で20分間激しく撹拌し
た後、不溶物を濾過し、1%(v/v)の濃アンモニア水を含
むエタノール各 1.5 mlで2回洗浄した。濾液と洗液を
合わせ、減圧濃縮して得られた残さ 28 mgを分離用TLC
(展開系:トルエン−アセトン(2:1))で精製して化合
物(11H) 10 mgを得た。 化合物(11H)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4677NO16 (3) マススペクトル (SIMS) : m/z 900 (M+H)+ (4) TLCにおけるRf値 : 0.32(展開系:トルエ
ン−アセトン(3:1)) (5) 比旋光度 : [α]D 19 -43°(c1.0, CH3OH) (6) 明瞭な融点を示さず、90〜93℃付近で熔融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.74(dd, 2-H), 5.13(br
d, 3-H), 3.26(br d, 4-H), 3.57(s, 4-OCH3), 3.88(br
d, 5-H), 2.13(br t, 6-H), 0.93(br ddd, 7-H), 1.54
(br dt, 7-H), 1.89(m, 8-H), 3.90(dd, 9-H), 5.46(d
d, 10-H), 6.62(dd, 11-H), 6.10(br dd, 12-H), 5.83
(ddd, 13-H), 2.17(dt, 14-H), 5.00(ddq, 15-H), 1.26
(d, 16-H3),2.28(br dd, 17-H), 2.85(br dd, 17-H),
9.64(br s, 18-H), 0.98(d, 19-H3),2.50(dq, 3-OCOCH 2
CH3), 2.64(dq, 3-OCOCH 2CH3), 1.23(t, 3-OCOCH2CH3 ),
4.64(q, 9-OCH(OCH2CH3)CH3), 3.43(dq, 9-OCH(OCH 2CH
3)CH3), 3.50(dq, 9-OCH(OCH 2CH3)CH3), 1.14(t, 9-OCH
(OCH2CH3 )CH3), 1.22(d, 9-OCH(OCH2CH3)CH3 ), 4.53(d,
1'-H), 3.46(t, 4'-H), 3.29(dq, 5'-H), 1.16(d, 6'-
H3), 2.60(s, 3'-N(CH3)2), 4.93(d, 1"-H), 1.67(dd,
2"-Hax), 2.29(d, 2"-Heq), 1.11(s, 3"-CH3),4.73(d,
4"-H), 4.54(dq, 5"-H), 1.08(d, 6"-H3), 3.26(s, 3"-
OCH3), 2.43(apparent q, 4"-OCOCH 2CH3), 2.44(ap. q,
4"-OCOCH 2CH3), 1.20(t, 4"-OCOCH2CH3 )
Example 10 Compound (11H) (in the formula (VIII), R 1 is an ethyl group
, R 4 is a propionyl group, and R 5 is 1-ethoxy
Compound (10H) among compounds represented by cyethyl group
After dissolving Ri induced isomer) of preparation the compound (10H) 30 mg of ethanol 0.35 ml, a 0.75 ml of Raney nickel was controlled activity in the same manner as in Example 1, the above solution along with 0.40 ml of ethanol added. This was vigorously stirred for 20 minutes at room temperature, then the insoluble matter was filtered off, and washed twice with 1.5 ml of ethanol each containing 1% (v / v) concentrated aqueous ammonia. The filtrate and washings were combined and concentrated under reduced pressure.
(Development system: toluene-acetone (2: 1)) to obtain 10 mg of compound (11H). Physicochemical properties of compound (11H) (1) Color and shape: colorless solid (2) Molecular formula: C 46 H 77 NO 16 (3) Mass spectrum (SIMS): m / z 900 (M + H) + (4) Rf value in TLC: 0.32 (Development system: Toluene-acetone (3: 1)) (5) Specific rotation: [α] D 19 -43 ° (c1.0, CH 3 OH) (6) Clear melting point Melting around 90-93 ℃ (7) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.26 (br d, 2-H), 2.74 (dd, 2-H), 5.13 (br
d, 3-H), 3.26 (br d, 4-H), 3.57 (s, 4-OCH 3 ), 3.88 (br
d, 5-H), 2.13 (br t, 6-H), 0.93 (br ddd, 7-H), 1.54
(br dt, 7-H), 1.89 (m, 8-H), 3.90 (dd, 9-H), 5.46 (d
d, 10-H), 6.62 (dd, 11-H), 6.10 (br dd, 12-H), 5.83
(ddd, 13-H), 2.17 (dt, 14-H), 5.00 (ddq, 15-H), 1.26
(d, 16-H 3 ), 2.28 (br dd, 17-H), 2.85 (br dd, 17-H),
9.64 (br s, 18-H), 0.98 (d, 19-H 3 ), 2.50 (dq, 3-OCOC H 2
CH 3 ), 2.64 (dq, 3-OCOC H 2 CH 3 ), 1.23 (t, 3-OCOCH 2 C H 3 ),
4.64 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 3.43 (dq, 9-OCH (OC H 2 CH
3 ) CH 3 ), 3.50 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 1.14 (t, 9-OCH
(OCH 2 C H 3 ) CH 3 ), 1.22 (d, 9-OCH (OCH 2 CH 3 ) C H 3 ), 4.53 (d,
1'-H), 3.46 (t, 4'-H), 3.29 (dq, 5'-H), 1.16 (d, 6'-
H 3 ), 2.60 (s, 3'-N (CH 3 ) 2 ), 4.93 (d, 1 "-H), 1.67 (dd,
2 "-Hax), 2.29 (d, 2" -Heq), 1.11 (s, 3 "-CH 3 ), 4.73 (d,
4 "-H), 4.54 (dq, 5" -H), 1.08 (d, 6 "-H 3 ), 3.26 (s, 3"-
OCH 3 ), 2.43 (apparent q, 4 "-OCOC H 2 CH 3 ), 2.44 (ap. Q,
4 "-OCOC H 2 CH 3 ), 1.20 (t, 4" -OCOCH 2 C H 3 )

【0047】実施例11化合物(11L)(式(VIII)において、R1がエチル基
で表され、R4がプロピオニル基で表され、R5が1-エトキ
シエチル基で表される化合物のうち化合物(10L)よ
り誘導される異性体)の製造法 化合物(10L) 150 mgをエタノール 2.0 mlに溶解し
た後、ラネーニッケル3.8 mlを実施例1と同様の方法で
活性をコントロールし、 1.8 mlのエタノールと共に上
記溶液に加えた。これを室温で20分間激しく撹拌した
後、不溶物を濾過し、1%(v/v)の濃アンモニア水を含む
エタノール各 4.0 mlで2回洗浄した。濾液と洗液を合
わせ、減圧濃縮して得られた残さ 145 mgを分離用TLC
(展開系:トルエン−アセトン(2:1))で精製して化合
物(11L) 32 mgを得た。 化合物(11L)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4677NO16 (3) マススペクトル (SIMS) : m/z 900 (M+H)+ (4) TLCにおけるRf値 : 0.32(展開系:トルエ
ン−アセトン(3:1)) (5) 比旋光度 : [α]D 19 -65°(c1.0, CH3OH) (6) 融点 : 明瞭な融点を示さず、87〜90℃付近
で熔融 (7) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 5.13(br
d, 3-H), 3.26(br d, 4-H), 3.57(s, 4-OCH3), 3.88(br
d, 5-H), 2.13(br t, 6-H), 0.94(br ddd, 7-H), 1.55
(br dt, 7-H), 1.88(m, 8-H), 3.75(dd, 9-H), 5.55(d
d, 10-H), 6.59 (dd, 11-H), 6.09(br dd, 12-H), 5.80
(ddd, 13-H), 2.16(dt, 14-H), 5.01(ddq, 15-H), 1.26
(d, 16-H3),2.25(br dd, 17-H), 2.86(br dd, 17-H),
9.64(br s, 18-H), 2.52(dq, 3-OCOCH 2CH3), 2.64(dq,
3-OCOCH 2CH3), 1.23(t, 3-OCOCH2CH3 ), 3.36(dq, 9-OCH
(OCH 2CH3)CH3), 3.63(dq, 9-OCH(OCH 2CH3)CH3), 1.14
(t, 9-OCH(OCH2CH3 )CH3), 1.25(d, 9-OCH(OCH2CH3)C
H3 ), 4.52(d, 1'-H), 3.21(dd, 2'-H), 2.42(t, 3'-H),
3.45(t, 4'-H), 3.29(dq, 5'-H), 1.16(d, 6'-H3), 2.
57(s, 3'-N(CH3)2), 4.92(d,1"-H), 1.67(dd, 2"-Hax),
2.29(d, 2"-Heq), 1.10(s, 3"-CH3), 4.72(d, 4"-H),
4.55(dq, 5"-H), 1.08(d, 6"-H3), 3.26(s, 3"-OCH3),
2.43(apparent q, 4"-OCOCH 2CH3), 2.44(ap. q, 4"-OCO
CH 2CH3), 1.18(t, 4"-OCOCH2CH3 )
Example 11Compound (11L) (in the formula (VIII), R 1 is an ethyl group
, R 4 is a propionyl group, and R 5 is 1-ethoxy
Compound (10 L) among compounds represented by cyethyl group
Isomer) Dissolve 150 mg of compound (10 L) in 2.0 ml of ethanol
Then, 3.8 ml of Raney nickel was treated in the same manner as in Example 1.
Control the activity and mix with 1.8 ml ethanol.
It was added to the above solution. This was stirred vigorously for 20 minutes at room temperature
After that, the insoluble matter is filtered and contains 1% (v / v) concentrated aqueous ammonia.
It was washed twice with 4.0 ml each of ethanol. Combine the filtrate and wash
And concentrate the residue under reduced pressure to obtain 145 mg of the residue, which is then separated by TLC for separation.
(Development system: toluene-acetone (2: 1))
32 mg of the product (11 L) was obtained. Physicochemical properties of compound (11L) (1) Color and shape: Colorless solid (2) Molecular formula: C46H77NO16 (3) Mass spectrum (SIMS): m / z 900 (M + H)+ (4) Rf value in TLC: 0.32 (Development system: Torue
-Acetone (3: 1)) (5) Specific rotation: [α]D 19 -65 ° (c1.0, CH3OH) (6) Melting point: No clear melting point, around 87-90 ° C
Melting with (7)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 5.13 (br
d, 3-H), 3.26 (br d, 4-H), 3.57 (s, 4-OCH3), 3.88 (br
 d, 5-H), 2.13 (br t, 6-H), 0.94 (br ddd, 7-H), 1.55
(br dt, 7-H), 1.88 (m, 8-H), 3.75 (dd, 9-H), 5.55 (d
d, 10-H), 6.59 (dd, 11-H), 6.09 (br dd, 12-H), 5.80
(ddd, 13-H), 2.16 (dt, 14-H), 5.01 (ddq, 15-H), 1.26
(d, 16-H3), 2.25 (br dd, 17-H), 2.86 (br dd, 17-H),
9.64 (br s, 18-H), 2.52 (dq, 3-OCOCH 2CH3), 2.64 (dq,
3-OCOCH 2CH3), 1.23 (t, 3-OCOCH2CH 3 ), 3.36 (dq, 9-OCH
(OCH 2CH3) CH3), 3.63 (dq, 9-OCH (OCH 2CH3) CH3), 1.14
(t, 9-OCH (OCH2CH 3 ) CH3), 1.25 (d, 9-OCH (OCH2CH3) C
H 3 ), 4.52 (d, 1'-H), 3.21 (dd, 2'-H), 2.42 (t, 3'-H),
 3.45 (t, 4'-H), 3.29 (dq, 5'-H), 1.16 (d, 6'-H3), 2.
57 (s, 3'-N (CH3)2), 4.92 (d, 1 "-H), 1.67 (dd, 2" -Hax),
 2.29 (d, 2 "-Heq), 1.10 (s, 3" -CH3), 4.72 (d, 4 "-H),
4.55 (dq, 5 "-H), 1.08 (d, 6" -H3), 3.26 (s, 3 "-OCH3),
2.43 (apparent q, 4 "-OCOCH 2CH3), 2.44 (ap. Q, 4 "-OCO
CH 2CH3), 1.18 (t, 4 "-OCOCH2CH 3 )

【0048】実施例12化合物(12)(式(IX)において、R1がエチル基で表
され、R4がプロピオニル基で表される化合物)(特願平
5-169418)の製造法 化合物(11H) 60 mgを5%酢酸水溶液 4.5 mlとアセ
トニトリル 1.5 mlの混合溶液に溶解した後、室温で1
6時間反応させた。反応液を減圧濃縮して得られた残さ
をクロロホルム 10 mlに溶解した後、飽和炭酸水素ナト
リウム水溶液 10 mlで3回および飽和塩化ナトリウム水
溶液 10 mlで順次洗浄した。クロロホルム層を無水硫酸
ナトリウムで乾燥後これを濾過し、濾液を減圧濃縮して
得られた残さ 56 mgを分離用TLC(展開系:クロロホル
ム−メタノール(10:1))で精製し、化合物(12) 50
mgを得た。
Example 12 Compound (12) (in the formula (IX), R 1 represents an ethyl group.
Compound in which R 4 is a propionyl group)
5-169418) Production method 60 mg of compound (11H) was dissolved in a mixed solution of 4.5 ml of 5% aqueous acetic acid solution and 1.5 ml of acetonitrile, and the mixture was mixed with 1
The reaction was performed for 6 hours. The reaction mixture was concentrated under reduced pressure, the obtained residue was dissolved in 10 ml of chloroform, and then the mixture was washed 3 times with 10 ml of saturated aqueous sodium hydrogen carbonate solution and successively with 10 ml of saturated aqueous sodium chloride solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 56 mg of the residue, which was purified by preparative TLC (developing system: chloroform-methanol (10: 1)) to give the compound (12 ) 50
to obtain mg.

【0049】実施例13化合物(12)の製造法 化合物(11L) 30 mgを5%酢酸水溶液 2.4 mlとアセ
トニトリル 0.8 mlの混合溶液に溶解した後、室温で1
6時間反応させた。反応液を減圧濃縮して得られた残さ
をクロロホルム 5.0 mlに溶解した後、飽和炭酸水素ナ
トリウム水溶液各 5.0 mlで3回および飽和塩化ナトリ
ウム水溶液 5.0 mlで順次洗浄した。クロロホルム層を
無水硫酸ナトリウムで乾燥後これを濾過し、濾液を減圧
濃縮して得られた残さ 28 mgを分離用TLC(展開系:ク
ロロホルム−メタノール(10:1))で精製し、化合物(1
2) 24 mgを得た。
Example 13 Method for producing compound (12) 30 mg of compound (11 L) was dissolved in a mixed solution of 2.4 ml of a 5% aqueous acetic acid solution and 0.8 ml of acetonitrile, and the mixture was allowed to stand at room temperature for 1 hour.
The reaction was performed for 6 hours. The reaction mixture was concentrated under reduced pressure, the residue obtained was dissolved in 5.0 ml of chloroform, and the mixture was washed 3 times with 5.0 ml of saturated aqueous sodium hydrogen carbonate solution and successively with 5.0 ml of saturated aqueous sodium chloride solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 28 mg of the residue, which was purified by preparative TLC (developing system: chloroform-methanol (10: 1)) to give compound (1
2) 24 mg was obtained.

【0050】実施例14化合物(13)(式(IV)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5が1-エトキシエ
チル基で表される化合物)の製造法 ジョサマイシン 10.0 gを塩化メチレン 300 mlとエチル
ビニルエーテル 16 mlの混合溶液に溶解した後、PPTS
5.40 gを加え、室温で4日間反応させた。反応液を飽和
炭酸水素ナトリウム水溶液 1.0 Lに徐々に加え、クロロ
ホルム 0.80 Lで抽出した。クロロホルム層を5%硫酸水
素カリウム水溶液 1.0 L、飽和炭酸水素ナトリウム水溶
液 1.0 L及び飽和塩化ナトリウム水溶液 1.0 Lで順次洗
浄した。クロロホルム層を無水硫酸ナトリウムで乾燥後
これを濾過し、濾液を減圧濃縮して得られた残さ 12.0
gをシリカゲルカラムクロマトグラフィー(600 g:クロ
ロホルム−メタノール(50:1))で精製して、化合物(1
3) 8.40 gを得た。 化合物(13)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4677NO16 (3) マススペクトル (EIMS) : m/z 899 (M)+ (4) 比旋光度 : [α]D 16 -68°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、105〜108℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.73(dd, 2-H), 2.75(dd, 2-H), 5.12(br d,
3-H), 3.24(br d, 4-H), 3.54(s, 4-OCH3), 3.90(br
d, 5-H), 1.45(br dt, 7-H), 1.90(m, 8-H), 3.75(dd,
9-H), 3.89(dd, 9-H), 5.46(dd, 10-H), 5.55(dd, 10-
H), 6.56(dd, 11-H), 6.58(dd, 11-H), 6.08(br dd, 12
-H), 5.76(ddd, 13-H), 5.81(ddd, 13-H), 5.04(ddq, 1
5-H), 1.27(d,16-H3), 2.84(br dd, 17-H), 2.85(br d
d, 17-H), 9.64(s, 18-H), 9.65(s, 18-H), 0.98(d, 19
-H3), 0.99(d, 19-H3), 4.63(q, 9-OCH(OCH2CH3)CH3),
4.64(q,9-OCH(OCH2CH3)CH3), 3.35(dq, 9-OCH(OCH 2CH3)
CH3), 3.42(dq, 9-OCH(OCH 2CH3)CH3), 3.63(dq, 9-OCH
(OCH 2CH3)CH3), 1.14(t, 9-OCH(OCH2CH3 )CH3), 1.23(d,
9-OCH(OCH2CH3)CH3 ), 1.25(d, 9-OCH(OCH2CH3)CH3 ), 4.
43(d, 1'-H), 3.28(t, 4'-H), 1.19(d, 6'-H3), 2.52
(s, 3'-N(CH3)2), 5.07(d, 1"-H), 1.85(dd, 2"-Hax),
2.02(d, 2"-Heq), 1.12(s, 3"-CH3), 4.63(d, 4"-H),
4.46(dq, 5"-H), 1.14(d, 6"-H3), 0.98(d, 4"-OCOCH2C
H(CH3)2 )
Example 14 Compound (13) (in formula (IV), R 1 represents a methyl group.
R 4 is an isovaleryl group, and R 5 is 1-ethoxyethyl.
Preparation method of compound represented by tyl group) 10.0 g of Josamycin was dissolved in a mixed solution of 300 ml of methylene chloride and 16 ml of ethyl vinyl ether, and then PPTS
5.40 g was added and reacted at room temperature for 4 days. The reaction solution was gradually added to 1.0 L of saturated sodium hydrogen carbonate aqueous solution, and extracted with 0.80 L of chloroform. The chloroform layer was washed successively with 1.0% aqueous 5% potassium hydrogen sulfate solution, 1.0 L saturated aqueous sodium hydrogen carbonate solution and 1.0 L saturated aqueous sodium chloride solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a residue of 12.0.
g was purified by silica gel column chromatography (600 g: chloroform-methanol (50: 1)) to give compound (1
3) Obtained 8.40 g. Physicochemical properties of compound (13) (1) Color and shape: colorless solid (2) Molecular formula: C 46 H 77 NO 16 (3) Mass spectrum (EIMS): m / z 899 (M) + (4) Specific rotation Degree: [α] D 16 -68 ° (c1.0, CH 3 OH) (5) Melting point: Melting at 105 to 108 ° C without showing clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.73 (dd, 2-H), 2.75 (dd, 2-H), 5.12 (br d,
3-H), 3.24 (br d, 4-H), 3.54 (s, 4-OCH 3 ), 3.90 (br
d, 5-H), 1.45 (br dt, 7-H), 1.90 (m, 8-H), 3.75 (dd,
9-H), 3.89 (dd, 9-H), 5.46 (dd, 10-H), 5.55 (dd, 10-
H), 6.56 (dd, 11-H), 6.58 (dd, 11-H), 6.08 (br dd, 12
-H), 5.76 (ddd, 13-H), 5.81 (ddd, 13-H), 5.04 (ddq, 1
5-H), 1.27 (d, 16-H 3 ), 2.84 (br dd, 17-H), 2.85 (br d
d, 17-H), 9.64 (s, 18-H), 9.65 (s, 18-H), 0.98 (d, 19
-H 3 ), 0.99 (d, 19-H 3 ), 4.63 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ),
4.64 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 3.35 (dq, 9-OCH (OC H 2 CH 3 )
CH 3 ), 3.42 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 3.63 (dq, 9-OCH
(OC H 2 CH 3 ) CH 3 ), 1.14 (t, 9-OCH (OCH 2 C H 3 ) CH 3 ), 1.23 (d,
9-OCH (OCH 2 CH 3 ) C H 3 ), 1.25 (d, 9-OCH (OCH 2 CH 3 ) C H 3 ), 4.
43 (d, 1'-H), 3.28 (t, 4'-H), 1.19 (d, 6'-H 3 ), 2.52
(s, 3'-N (CH 3 ) 2 ), 5.07 (d, 1 "-H), 1.85 (dd, 2" -Hax),
2.02 (d, 2 "-Heq), 1.12 (s, 3" -CH 3 ), 4.63 (d, 4 "-H),
4.46 (dq, 5 "-H), 1.14 (d, 6" -H 3 ), 0.98 (d, 4 "-OCOCH 2 C
H (C H 3 ) 2 )

【0051】実施例15化合物(14)(式(V)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5が1-エトキシエ
チル基で表される化合物)の製造法 化合物(13) 7.70 gをアセトニトリル 231 mlに溶解
した後、無水酢酸 1.6mlを加え40℃で16時間反応させ
た。1規定アンモニア水溶液 25 mlを滴下し、室温で1
0分間放置した。反応液を減圧濃縮して得られた残さを
クロロホルム800 mlに溶解し、飽和炭酸水素ナトリウム
水溶液 800 mlおよび飽和塩化ナトリウム水溶液 800 ml
で順次洗浄した。クロロホルム層を無水硫酸ナトリウム
で乾燥後これを濾過し、濾液を減圧濃縮した。得られた
残さ 7.90 gをシリカゲルカラムクロマトグラフィー(7
00 g:ヘキサン−酢酸エチル(1:1))で精製して化合物
(14)5.10 gを得た。 化合物(14)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4879NO17 (3) マススペクトル (FDMS) : m/z 942 (M+H)+ (4) 比旋光度 : [α]D 19 -70°(c1.0, CHCl3) (5) 融点 : 明瞭な融点を示さず、110〜113℃で
熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.25(br d, 2-H), 2.72(dd, 2-H), 5.10(br
d, 3-H), 3.18(br d, 4-H), 3.49(s, 4-OCH3), 3.91(br
d, 5-H), 0.86(br ddd, 7-H), 1.43(br dt, 7-H), 3.7
2(dd, 9-H), 3.86(dd, 9-H), 5.46(dd, 10-H), 5.54(d
d, 10-H), 6.55(dd, 11-H), 6.58(dd, 11-H), 6.05(br
dd, 12-H), 5.76(ddd, 13-H), 5.81(ddd, 13-H), 2.12
(dt, 14-H), 2.45(br dt, 14-H), 5.01(ddq, 15-H), 1.
26(d, 16-H3), 2.83(br dd, 17-H), 9.63(s, 18-H), 9.
64(s, 18-H), 2.29(s, 3-OCOCH3), 3.34(dq, 9-OCH(OCH
2CH3)CH 3), 3.41(dq, 9-OCH(OCH 2CH3)CH3), 3.63(dq, 9
-OCH(OCH 2CH3)CH3), 1.14(t, 9-OCH(OCH2CH3 )CH3), 1.2
2(d, 9-OCH(OCH2CH3)CH3 ), 1.24(d, 9-OCH(OCH2CH3)C
H3 ), 4.99(dd, 2'-H), 2.69(t, 3'-H), 1.18(d, 6'-
H3), 2.02(s, 2'-OCOCH3), 2.41(s, 3'-N(CH3)2), 5.06
(d, 1"-H), 1.84(dd, 2"-Hax), 2.01(d, 2"-Heq), 1.12
(s, 3"-CH3), 4.38(dq, 5"-H), 1.13(d, 6"-H3), 0.98
(d, 4"-OCOCH2CH(CH3)2 )
Example 15Compound (14) (in formula (V), R 1 represents a methyl group.
R 4 is an isovaleryl group, and R 5 is 1-ethoxyethyl.
Compound represented by tyl group) Dissolve 7.70 g of compound (13) in 231 ml of acetonitrile
After that, add 1.6 ml of acetic anhydride and react at 40 ℃ for 16 hours.
Was. Add 25 ml of 1N aqueous ammonia solution, and add 1 at room temperature.
It was left for 0 minutes. The residue obtained by concentrating the reaction solution under reduced pressure
Dissolved in 800 ml of chloroform and saturated sodium bicarbonate
800 ml aqueous solution and 800 ml saturated aqueous sodium chloride solution
Was sequentially washed. Chloroform layer is anhydrous sodium sulfate
After drying with, this was filtered, and the filtrate was concentrated under reduced pressure. Got
7.90 g of the residue was subjected to silica gel column chromatography (7
00 g: hexane-ethyl acetate (1: 1))
(14) 5.10 g was obtained. Physicochemical properties of compound (14) (1) Color and shape: colorless solid (2) molecular formula: C48H79NO17 (3) Mass spectrum (FDMS): m / z 942 (M + H)+ (4) Specific rotation: [α]D 19 -70 ° (c1.0, CHCl3) (5) Melting point: No clear melting point at 110-113 ° C
Melting (6)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.25 (br d, 2-H), 2.72 (dd, 2-H), 5.10 (br
d, 3-H), 3.18 (br d, 4-H), 3.49 (s, 4-OCH3), 3.91 (br
 d, 5-H), 0.86 (br ddd, 7-H), 1.43 (br dt, 7-H), 3.7
2 (dd, 9-H), 3.86 (dd, 9-H), 5.46 (dd, 10-H), 5.54 (d
d, 10-H), 6.55 (dd, 11-H), 6.58 (dd, 11-H), 6.05 (br
dd, 12-H), 5.76 (ddd, 13-H), 5.81 (ddd, 13-H), 2.12
(dt, 14-H), 2.45 (br dt, 14-H), 5.01 (ddq, 15-H), 1.
26 (d, 16-H3), 2.83 (br dd, 17-H), 9.63 (s, 18-H), 9.
64 (s, 18-H), 2.29 (s, 3-OCOCH3), 3.34 (dq, 9-OCH (OCH
2CH3) CH 3), 3.41 (dq, 9-OCH (OCH 2CH3) CH3), 3.63 (dq, 9
-OCH (OCH 2CH3) CH3), 1.14 (t, 9-OCH (OCH2CH 3 ) CH3), 1.2
2 (d, 9-OCH (OCH2CH3) CH 3 ), 1.24 (d, 9-OCH (OCH2CH3) C
H 3 ), 4.99 (dd, 2'-H), 2.69 (t, 3'-H), 1.18 (d, 6'-
H3), 2.02 (s, 2'-OCOCH3), 2.41 (s, 3'-N (CH3)2), 5.06
(d, 1 "-H), 1.84 (dd, 2" -Hax), 2.01 (d, 2 "-Heq), 1.12
(s, 3 "-CH3), 4.38 (dq, 5 "-H), 1.13 (d, 6" -H3), 0.98
(d, 4 "-OCOCH2CH (CH 3 ) 2 )

【0052】実施例16化合物(15)(式(VI)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5が1-エトキシエ
チル基で表される化合物)の製造法 化合物(14) 5.00 gをDMSO 150 mlと無水酢酸 15 ml
の混合溶液に溶解した後、30℃で40時間反応させた。
反応液をトルエン 1.0 Lに徐々に加え、水 1.0Lで3回
洗浄した。トルエン層を無水硫酸ナトリウムで乾燥後こ
れを濾過し、濾液を減圧濃縮した。得られた残さ 6.41g
をシリカゲルカラムクロマトグラフィー(500 g:ヘキサ
ン−酢酸エチル(1:1))で精製して、化合物(15) 2.
25 gを得た。 化合物(15)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C5083NO17S (3) マススペクトル (FDMS) : m/z 1002 (M+H)
+ (4) 比旋光度 : [α]D 16 -87°(c1.0, CHCl3) (5) 明瞭な融点を示さず、102〜105℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.25(br d, 2-H), 2.72(dd, 2-H), 2.73(dd,
2-H), 5.10(br d, 3-H), 3.18(br d, 4-H), 3.50(s, 4
-OCH3), 3.51(s, 4-OCH3), 3.89(br d, 5-H), 0.85(br
ddd, 7-H), 1.43(br dt, 7-H), 1.87(m, 8-H), 3.73(d
d, 9-H), 3.86(dd, 9-H), 5.45(dd, 10-H),5.54(dd, 10
-H), 6.54(dd, 11-H), 6.58(dd, 11-H), 6.05(br dd, 1
2-H), 5.76(ddd, 13-H), 5.82(ddd, 13-H), 2.15(dt, 1
4-H), 2.45(br dt, 14-H), 5.01(ddq, 15-H), 1.26(d,
16-H3), 2.85(br dd, 17-H), 9.63(s, 18-H), 9.64(s,
18-H), 0.99(d, 19-H3), 3.35(dq, 9-OCH(OCH 2CH3)C
H3), 3.41(dq, 9-OCH(OCH 2CH3)CH 3), 3.63(dq, 9-OCH(O
CH 2CH3)CH3), 1.14(br t, 9-OCH(OCH2CH3 )CH3), 1.22
(d,9-OCH(OCH2CH3)CH3 ), 1.24(d, 9-OCH(OCH2CH3)CH3 ),
5.10(d, 1'-H), 4.93(dd,2'-H), 2.68(t, 3'-H), 3.16
(t, 4'-H), 3.27(dq, 5'-H), 1.14(d, 6'-H3), 2.01(s,
2'-OCOCH3), 2.42(s, 3'-N(CH3)2), 4.81(d, 1"-H),
1.68(dd, 2"-Hax), 1.18(s, 3"-CH3), 4.57(dq, 5"-H),
1.05(d, 6"-H3), 4.50(d, 3"-OCH 2SCH3), 4.64, 4.65
(2×d, 4"-H, 3"-OCH 2SCH3), 2.20(s, 3"-OCH2SCH3 ),
0.98(d, 4"-OCOCH2CH(CH3)2 )
Example 16Compound (15) (in formula (VI), R 1 represents a methyl group.
R 4 is an isovaleryl group, and R 5 is 1-ethoxyethyl.
Compound represented by tyl group) Compound (14) (5.00 g) in DMSO (150 ml) and acetic anhydride (15 ml)
After being dissolved in the mixed solution of, the reaction was carried out at 30 ° C. for 40 hours.
The reaction solution was gradually added to 1.0 L of toluene, and 1.0 L of water was added 3 times.
Washed. After drying the toluene layer with anhydrous sodium sulfate,
It was filtered and the filtrate was concentrated under reduced pressure. The residue obtained 6.41g
Silica gel column chromatography (500 g: hexa
-Ethyl acetate (1: 1)) to give compound (15) 2.
Got 25 g. Physicochemical properties of compound (15) (1) Color and shape: colorless solid (2) molecular formula: C50H83NO17S (3) Mass spectrum (FDMS): m / z 1002 (M + H)
+ (4) Specific rotation: [α]D 16 -87 ° (c1.0, CHCl3) (5) Melting around 102-105 ℃ without showing clear melting point (6)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.25 (br d, 2-H), 2.72 (dd, 2-H), 2.73 (dd,
 2-H), 5.10 (br d, 3-H), 3.18 (br d, 4-H), 3.50 (s, 4
-OCH3), 3.51 (s, 4-OCH3), 3.89 (br d, 5-H), 0.85 (br
ddd, 7-H), 1.43 (br dt, 7-H), 1.87 (m, 8-H), 3.73 (d
d, 9-H), 3.86 (dd, 9-H), 5.45 (dd, 10-H), 5.54 (dd, 10
-H), 6.54 (dd, 11-H), 6.58 (dd, 11-H), 6.05 (br dd, 1
2-H), 5.76 (ddd, 13-H), 5.82 (ddd, 13-H), 2.15 (dt, 1
4-H), 2.45 (br dt, 14-H), 5.01 (ddq, 15-H), 1.26 (d,
16-H3), 2.85 (br dd, 17-H), 9.63 (s, 18-H), 9.64 (s,
18-H), 0.99 (d, 19-H3), 3.35 (dq, 9-OCH (OCH 2CH3) C
H3), 3.41 (dq, 9-OCH (OCH 2CH3) CH 3), 3.63 (dq, 9-OCH (O
CH 2CH3) CH3), 1.14 (br t, 9-OCH (OCH2CH 3 ) CH3), 1.22
(d, 9-OCH (OCH2CH3) CH 3 ), 1.24 (d, 9-OCH (OCH2CH3) CH 3 ),
 5.10 (d, 1'-H), 4.93 (dd, 2'-H), 2.68 (t, 3'-H), 3.16
(t, 4'-H), 3.27 (dq, 5'-H), 1.14 (d, 6'-H3), 2.01 (s,
 2'-OCOCH3), 2.42 (s, 3'-N (CH3)2), 4.81 (d, 1 "-H),
1.68 (dd, 2 "-Hax), 1.18 (s, 3" -CH3), 4.57 (dq, 5 "-H),
 1.05 (d, 6 "-H3), 4.50 (d, 3 "-OCH 2SCH3), 4.64, 4.65
(2 × d, 4 "-H, 3" -OCH 2SCH3), 2.20 (s, 3 "-OCH2SCH 3 ),
0.98 (d, 4 "-OCOCH2CH (CH 3 ) 2 )

【0053】実施例17化合物(16)(式(VII)において、R1がメチル基で
表され、R4がイソバレリル基で表され、R5が1-エトキシ
エチル基で表される化合物)の製造法 化合物(15) 2.20 gをメタノール 65 mlに溶解した
後、室温で40時間反応させた。反応液を減圧濃縮し、
化合物(16) 2.10 gを得た。 化合物(16)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4881NO16S (3) マススペクトル (FDMS) : m/z 959 (M)+ (4) 比旋光度 : [α]D 18 -75°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、105〜107℃付
近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 2.76(dd,
2-H), 5.11(br d, 3-H), 3.58(s, 4-OCH3), 3.91(br
d, 5-H), 0.92(br ddd, 7-H), 1.54(br dt, 7-H), 1.89
(m, 8-H), 3.73(dd,9-H), 3.88(dd, 9-H), 5.46(dd, 10
-H), 5.55(dd, 10-H), 6.56(dd, 11-H), 6.60(dd, 11-
H), 6.09(br dd, 12-H), 5.77(ddd, 13-H), 5.82(ddd,
13-H), 2.13(dt, 14-H), 2.46(br dt, 14-H), 5.03(dd
q, 15-H), 1.27(d, 16-H3), 2.88(br dd, 17-H), 9.64
(s, 18-H), 9.65(s, 18-H), 2.28(s, 3-OCOCH3), 3.35
(dq, 9-OCH(OCH 2CH3)CH3), 3.41(dq, 9-OCH(OCH 2CH3)CH
3), 3.49(dq, 9-OCH(OCH 2CH3)CH3), 3.63(dq, 9-OCH(OC
H 2CH3)CH3), 1.14(br t, 9-OCH(OCH2CH3 )CH3), 1.22(d,
9-OCH(OCH2CH3)CH3 ), 1.24(d, 9-OCH(OCH2CH3)CH3 ),
4.51(d, 1'-H), 1.15(d, 6'-H3), 2.57(s, 3'-N(C
H3)2), 4.92(d, 1"-H), 1.74(dd, 2"-Hax), 1.20(s, 3"
-CH 3), 4.56(dq, 5"-H), 1.08(d, 6"-H3), 4.52(d, 3"-
OCH 2SCH3), 4.65, 4.66(2×d, 4"-H, 3"-OCH 2SCH3), 2.
20(s, 3"-OCH2SCH3 ), 0.98(d, 4"-OCOCH2CH(CH3)2 )
Embodiment 17Compound (16) (in formula (VII), R 1 is a methyl group
R 4 is an isovaleryl group and R 5 is 1-ethoxy.
Method for producing compound represented by ethyl group) 2.20 g of compound (15) was dissolved in 65 ml of methanol.
Then, the mixture was reacted at room temperature for 40 hours. The reaction solution is concentrated under reduced pressure,
2.10 g of compound (16) was obtained. Physicochemical properties of compound (16) (1) Color and shape: colorless solid (2) molecular formula: C48H81NO16S (3) Mass spectrum (FDMS): m / z 959 (M)+ (4) Specific rotation: [α]D 18 -75 ° (c1.0, CH3OH) (5) Melting point: No clear melting point, with 105-107 ° C
Melting nearby (6)11 H NMR spectrum (400MHz, CDCl3) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 2.76 (dd,
 2-H), 5.11 (br d, 3-H), 3.58 (s, 4-OCH3), 3.91 (br
d, 5-H), 0.92 (br ddd, 7-H), 1.54 (br dt, 7-H), 1.89
(m, 8-H), 3.73 (dd, 9-H), 3.88 (dd, 9-H), 5.46 (dd, 10
-H), 5.55 (dd, 10-H), 6.56 (dd, 11-H), 6.60 (dd, 11-
H), 6.09 (br dd, 12-H), 5.77 (ddd, 13-H), 5.82 (ddd,
13-H), 2.13 (dt, 14-H), 2.46 (br dt, 14-H), 5.03 (dd
q, 15-H), 1.27 (d, 16-H3), 2.88 (br dd, 17-H), 9.64
(s, 18-H), 9.65 (s, 18-H), 2.28 (s, 3-OCOCH3), 3.35
(dq, 9-OCH (OCH 2CH3) CH3), 3.41 (dq, 9-OCH (OCH 2CH3) CH
3), 3.49 (dq, 9-OCH (OCH 2CH3) CH3), 3.63 (dq, 9-OCH (OC
H 2CH3) CH3), 1.14 (br t, 9-OCH (OCH2CH 3 ) CH3), 1.22 (d,
 9-OCH (OCH2CH3) CH 3 ), 1.24 (d, 9-OCH (OCH2CH3) CH 3 ),
4.51 (d, 1'-H), 1.15 (d, 6'-H3), 2.57 (s, 3'-N (C
H3)2), 4.92 (d, 1 "-H), 1.74 (dd, 2" -Hax), 1.20 (s, 3 "
-CH 3), 4.56 (dq, 5 "-H), 1.08 (d, 6" -H3), 4.52 (d, 3 "-
OCH 2SCH3), 4.65, 4.66 (2 × d, 4 "-H, 3" -OCH 2SCH3), 2.
20 (s, 3 "-OCH2SCH 3 ), 0.98 (d, 4 "-OCOCH2CH (CH 3 ) 2 )

【0054】実施例18化合物(17)(式(VIII)において、R1がメチル基で
表され、R4がイソバレリル基で表され、R5が1-エトキシ
エチル基で表される化合物)の製造法 化合物(16) 1.00 gをエタノール 25 mlに溶解した
後、ラネーニッケル 25mlを実施例1と同様の方法で活
性をコントロールし、 25 mlのエタノールと共に上記溶
液に加えた。これを室温で20分間激しく撹拌した後、
不溶物を濾過し、1%(v/v)の濃アンモニア水を含むエタ
ノール各 50 mlで2回洗浄した。濾液と洗液を合わせ、
減圧濃縮して得られた残さ 930 mgをシリカゲルカラム
クロマトグラフィー(100 g:トルエン−アセトン(1:
1))で精製して粗化合物(17) 614 mgを得た。これ
をシリカゲルカラムクロマトグラフィー(100 g:ヘキ
サン:酢酸エチル(1:1)→(1:2))で再精製して化合物
(17) 360 mgを得た。 化合物(17)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4779NO16 (3) マススペクトル (SIMS) : m/z 914 (M+H)+ (4) 比旋光度 : [α]D 16 -62°(c1.0, CH3OH) (5) 明瞭な融点を示さず、98〜101℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.75(dd, 2-H), 2.76(dd, 2-H), 5.12(br d,
3-H), 3.58(s, 4-OCH3), 3.91(br d, 5-H), 1.55(br d
t, 7-H), 1.89(m, 8-H), 3.73(dd, 9-H), 3.88(dd, 9-
H), 5.46(dd, 10-H), 5.55(dd, 10-H), 6.57(dd, 11-
H), 6.59(dd, 11-H), 6.09(br dd, 12-H), 5.77(ddd, 1
3-H), 5.82(ddd, 13-H), 2.13(dt, 14-H), 2.46(br dt,
14-H), 5.03(ddq, 15-H), 1.26(d, 16-H3), 2.88(br d
d, 17-H), 9.64(s, 18-H), 9.66(s, 18-H), 2.28(s, 3-
OCOCH3), 4.63(q, 9-OCH(OCH2CH3)CH3), 4.64(q, 9-OCH
(OCH2CH3)CH3), 3.35(dq, 9-OCH(OCH 2CH3)CH3), 3.42(d
q, 9-OCH(OCH 2CH3)CH3), 3.50(dq, 9-OCH(OCH 2CH3)C
H3), 3.63(dq, 9-OCH(OCH 2CH3)CH3), 1.14(br t, 9-OCH
(OCH2CH3 )CH3), 1.22(d, 9-OCH(OCH2CH3)CH3 ), 1.24(d,
9-OCH(OCH2CH3)CH3 ), 4.52(d, 1'-H), 3.46(t, 4'-H),
1.16(d, 6'-H3), 2.58(s, 3'-N(CH3)2), 4.93(d, 1"-
H), 1.10(s, 3"-CH3), 4.73(d, 4"-H), 4.54(dq, 5"-
H), 1.08(d, 6"-H3), 3.26(s, 3"-OCH3), 0.97(d, 4"-O
COCH2CH(CH3)2 )
Example 18 Compound (17) (in formula (VIII), R 1 is a methyl group
R 4 is an isovaleryl group and R 5 is 1-ethoxy.
Method for producing compound represented by ethyl group ) 1.00 g of compound (16) was dissolved in 25 ml of ethanol, and 25 ml of Raney nickel was added to the above solution together with 25 ml of ethanol to control the activity in the same manner as in Example 1. added. After stirring it vigorously for 20 minutes at room temperature,
The insoluble material was filtered and washed twice with 50 ml of ethanol each containing 1% (v / v) concentrated aqueous ammonia. Combine the filtrate and wash,
930 mg of the residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography (100 g: toluene-acetone (1:
Purification in (1)) gave 614 mg of crude compound (17). This was re-purified by silica gel column chromatography (100 g: hexane: ethyl acetate (1: 1) → (1: 2)) to obtain 360 mg of compound (17). Physicochemical properties of compound (17) (1) Color and shape: colorless solid (2) Molecular formula: C 47 H 79 NO 16 (3) Mass spectrum (SIMS): m / z 914 (M + H) + (4) Specific rotation: [α] D 16 -62 ° (c1.0, CH 3 OH) (5) No clear melting point, melting around 98-101 ° C (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.75 (dd, 2-H), 2.76 (dd, 2-H), 5.12 (br d,
3-H), 3.58 (s, 4-OCH 3 ), 3.91 (br d, 5-H), 1.55 (br d
t, 7-H), 1.89 (m, 8-H), 3.73 (dd, 9-H), 3.88 (dd, 9-
H), 5.46 (dd, 10-H), 5.55 (dd, 10-H), 6.57 (dd, 11-
H), 6.59 (dd, 11-H), 6.09 (br dd, 12-H), 5.77 (ddd, 1
3-H), 5.82 (ddd, 13-H), 2.13 (dt, 14-H), 2.46 (br dt,
14-H), 5.03 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.88 (br d
d, 17-H), 9.64 (s, 18-H), 9.66 (s, 18-H), 2.28 (s, 3-
OCOCH 3 ), 4.63 (q, 9-OC H (OCH 2 CH 3 ) CH 3 ), 4.64 (q, 9-OC H
(OCH 2 CH 3 ) CH 3 ), 3.35 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 3.42 (d
q, 9-OCH (OC H 2 CH 3 ) CH 3 ), 3.50 (dq, 9-OCH (OC H 2 CH 3 ) C
H 3 ), 3.63 (dq, 9-OCH (OC H 2 CH 3 ) CH 3 ), 1.14 (br t, 9-OCH
(OCH 2 C H 3 ) CH 3 ), 1.22 (d, 9-OCH (OCH 2 CH 3 ) C H 3 ), 1.24 (d,
9-OCH (OCH 2 CH 3 ) C H 3 ), 4.52 (d, 1'-H), 3.46 (t, 4'-H),
1.16 (d, 6'-H 3 ), 2.58 (s, 3'-N (CH 3) 2), 4.93 (d, 1 "-
H), 1.10 (s, 3 "-CH 3 ), 4.73 (d, 4" -H), 4.54 (dq, 5 "-
H), 1.08 (d, 6 "-H 3 ), 3.26 (s, 3" -OCH 3 ), 0.97 (d, 4 "-O
COCH 2 CH (C H 3 ) 2 )

【0055】実施例19化合物(18)(式(IX)において、R1がメチル基で表
され、R4がイソバレリル基で表される化合物)の製造法 化合物(17) 190 mgを5%酢酸水溶液 15 mlとアセト
ニトリル 5.0 mlの混合溶液に溶解した後、室温で16
時間反応させた。反応液を減圧濃縮して得られた残さを
クロロホルム 20 mlに溶解した後、飽和炭酸水素ナトリ
ウム水溶液 20mlで3回および飽和塩化ナトリウム水溶
液 20 mlで順次洗浄した。クロロホルム層を無水硫酸ナ
トリウムで乾燥後これを濾過し、濾液を減圧濃縮して得
られた残さ 192 mgを分離用TLC(展開系:クロロホルム
−メタノール−濃アンモニア水(30:1:0.1))で精製し、
化合物(18) 135 mgを得た。 化合物(18)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4371NO15 (3) マススペクトル (SIMS) : m/z 842 (M+H)+ (4) 比旋光度 : [α]D 17 -65°(c1.0, CH3OH) (5) 明瞭な融点を示さず、115〜117℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.74(dd, 2-H), 5.12(br d, 3-H), 3.26(br
d, 4-H), 3.58(s, 4-OCH3), 3.90(br d, 5-H), 0.92(br
ddd, 7-H), 1.58(br dt, 7-H), 1.89(m, 8-H), 4.05(d
d, 9-H), 5.62(dd,10-H), 6.64(dd, 11-H), 6.08(br d
d, 12-H), 5.76(ddd, 13-H), 2.46(br dt,14-H), 5.04
(ddq, 15-H), 1.26(d, 16-H3), 2.33(br dd, 17-H), 2.
88(br dd, 17-H), 9.64(s, 18-H), 0.98(d, 19-H3), 2.
28(s, 3-OCOCH3), 4.52(d, 1'-H), 3.21(dd, 2'-H), 2.
41(t, 3'-H), 3.46(t, 4'-H), 3.29(dq, 5'-H), 1.16
(d, 6'-H3), 2.57(s, 3'-N(CH3)2), 4.93(br d, 1"-H),
1.66(dd, 2"-Hax), 1.10(s, 3"-CH3), 4.72(d, 4"-H),
5.54(dq, 5"-H), 1.08(d, 6"-H3), 3.25(s, 3"-OCH3),
0.97(d, 4"-OCOCH2CH(CH3)2 )
Example 19 Compound (18) (in the formula (IX), R 1 represents a methyl group.
Is, after the R 4 is dissolved in a mixed solution of Preparation Compound (17) a 190 mg 5% aqueous acetic acid 15 ml and acetonitrile 5.0 ml of the compound represented by) with isovaleryl group, at room temperature 16
Allowed to react for hours. The reaction mixture was concentrated under reduced pressure, the resulting residue was dissolved in 20 ml of chloroform, and the mixture was washed 3 times with 20 ml of saturated aqueous sodium hydrogen carbonate solution and successively with 20 ml of saturated aqueous sodium chloride solution. The chloroform layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 192 mg of the residue, which was separated by TLC for separation (developing system: chloroform-methanol-concentrated aqueous ammonia (30: 1: 0.1)). Purified,
135 mg of compound (18) was obtained. Physicochemical properties of compound (18) (1) Color and shape: colorless solid (2) Molecular formula: C 43 H 71 NO 15 (3) Mass spectrum (SIMS): m / z 842 (M + H) + (4) Specific rotation: [α] D 17 -65 ° (c1.0, CH 3 OH) (5) No clear melting point, melting around 115-117 ° C (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.74 (dd, 2-H), 5.12 (br d, 3-H), 3.26 (br
d, 4-H), 3.58 (s, 4-OCH 3 ), 3.90 (br d, 5-H), 0.92 (br
ddd, 7-H), 1.58 (br dt, 7-H), 1.89 (m, 8-H), 4.05 (d
d, 9-H), 5.62 (dd, 10-H), 6.64 (dd, 11-H), 6.08 (br d
d, 12-H), 5.76 (ddd, 13-H), 2.46 (br dt, 14-H), 5.04
(ddq, 15-H), 1.26 (d, 16-H 3 ), 2.33 (br dd, 17-H), 2.
88 (br dd, 17-H), 9.64 (s, 18-H), 0.98 (d, 19-H 3 ), 2.
28 (s, 3-OCOCH 3 ), 4.52 (d, 1'-H), 3.21 (dd, 2'-H), 2.
41 (t, 3'-H), 3.46 (t, 4'-H), 3.29 (dq, 5'-H), 1.16
(d, 6'-H 3 ), 2.57 (s, 3'-N (CH 3 ) 2 ), 4.93 (br d, 1 "-H),
1.66 (dd, 2 "-Hax), 1.10 (s, 3" -CH 3 ), 4.72 (d, 4 "-H),
5.54 (dq, 5 "-H), 1.08 (d, 6" -H 3 ), 3.25 (s, 3 "-OCH 3 ),
0.97 (d, 4 "-OCOCH 2 CH (C H 3 ) 2 )

【0056】実施例20化合物(20)(式(VI)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5がプロピオニル
基で表される化合物)の製造法 化合物(19)(式(V)において、R1がメチル基で表
され、R4がイソバレリル基で表され、R5がプロピオニル
基で表される化合物)(特開昭49-10515) 22.0 gをDMS
O 500 mlと無水酢酸 50 mlの混合溶液に溶解した後、36
℃で16時間反応させた。反応液をトルエン 5.0 Lに徐
々に加え、水 5.0 Lで3回洗浄した。トルエン層を無水
硫酸ナトリウムで乾燥後これを濾過し、濾液を減圧濃縮
した。得られた残さ 30.0 gをシリカゲルカラムクロマ
トグラフィー(1.0 kg:トルエン−アセトン(8:1)→(7:
1))で精製して、化合物(20) 9.00 gを得た。 化合物(20)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4979NO17S (3) マススペクトル (SIMS) : m/z 986 (M+H)+ (4) 比旋光度 : [α]D 16 -90°(c1.0, CHCl3) (5) 明瞭な融点を示さず、114〜116℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.25(br d, 2-H), 2.71(dd, 2-H), 5.09(br
d, 3-H), 3.16(br d, 4-H), 3.49(s, 4-OCH3), 3.94(br
d, 5-H), 0.85(br dt, 7-H), 1.46(br dt, 7-H), 5.05
(dd, 9-H), 5.57(dd, 10-H), 6.69(dd, 11-H), 6.05(br
dd, 12-H), 5.85(ddd, 13-H), 2.45(br dt, 14-H), 4.
98(ddq, 15-H), 1.26(d, 16-H3), 2.58(br dd, 17-H),
2.82(br dd,17-H), 9.64(s, 18-H), 0.95(d, 19-H3),
2.30(s, 3-OCOCH3), 1.10(t, 9-OCOCH2CH3 ), 4.59(d,
1'-H), 4.90(dd, 2'-H), 2.67(t, 3'-H), 3.16(t, 4'-
H), 3.26(dq, 5'-H), 1.14(d, 6'-H3), 2.01(s, 2'-OCO
CH3), 2.42(s, 3'-N(CH3)2), 4.81(d, 1"-H), 1.68(dd,
2"-Hax), 1.18(s, 3"-CH3), 4.56(dq, 5"-H), 1.05(d,
6"-H3), 4.50(d, 3"-OCH 2SCH3), 4.63, 4.64(2×d, 4"-
H, 3"-OCH 2SCH3), 2.20(s, 3"-OCH2SCH3 ), 0.98(d, 4"-
OCOCH2CH(CH3)2 )
Example 20 Compound (20) (in formula (VI), R 1 represents a methyl group.
R 4 is an isovaleryl group and R 5 is propionyl
Compound represented by group (19) ( a compound represented by the formula (V), wherein R 1 is a methyl group, R 4 is an isovaleryl group, and R 5 is a propionyl group) (JP-A-49-10515) 22.0 g of DMS
After dissolving in a mixed solution of 500 ml O and 50 ml acetic anhydride,
Reaction was performed at 16 ° C. for 16 hours. The reaction solution was gradually added to 5.0 L of toluene and washed with 5.0 L of water three times. The toluene layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. 30.0 g of the obtained residue was subjected to silica gel column chromatography (1.0 kg: toluene-acetone (8: 1) → (7:
Purification by 1)) yielded 9.00 g of compound (20). Physicochemical properties of compound (20) (1) Color and shape: colorless solid (2) Molecular formula: C 49 H 79 NO 17 S (3) Mass spectrum (SIMS): m / z 986 (M + H) + (4) ) Specific rotation: [α] D 16 -90 ° (c1.0, CHCl 3 ) (5) Melting around 114-116 ℃ without showing clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.25 (br d, 2-H), 2.71 (dd, 2-H), 5.09 (br
d, 3-H), 3.16 (br d, 4-H), 3.49 (s, 4-OCH 3 ), 3.94 (br
d, 5-H), 0.85 (br dt, 7-H), 1.46 (br dt, 7-H), 5.05
(dd, 9-H), 5.57 (dd, 10-H), 6.69 (dd, 11-H), 6.05 (br
dd, 12-H), 5.85 (ddd, 13-H), 2.45 (br dt, 14-H), 4.
98 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.58 (br dd, 17-H),
2.82 (br dd, 17-H), 9.64 (s, 18-H), 0.95 (d, 19-H 3 ),
2.30 (s, 3-OCOCH 3 ), 1.10 (t, 9-OCOCH 2 C H 3 ), 4.59 (d,
1'-H), 4.90 (dd, 2'-H), 2.67 (t, 3'-H), 3.16 (t, 4'-
H), 3.26 (dq, 5'-H), 1.14 (d, 6'-H 3 ), 2.01 (s, 2'-OCO
CH 3 ), 2.42 (s, 3'-N (CH 3 ) 2 ), 4.81 (d, 1 "-H), 1.68 (dd,
2 "-Hax), 1.18 (s, 3" -CH 3 ), 4.56 (dq, 5 "-H), 1.05 (d,
6 "-H 3 ), 4.50 (d, 3" -OC H 2 SCH 3 ), 4.63, 4.64 (2 × d, 4 "-
H, 3 "-OC H 2 SCH 3 ), 2.20 (s, 3" -OCH 2 SC H 3 ), 0.98 (d, 4 "-
OCOCH 2 CH (C H 3 ) 2 )

【0057】実施例21化合物(21)(式(VII)において、R1がメチル基で
表され、R4がイソバレリル基で表され、R5がプロピオニ
ル基で表される化合物)の製造法 化合物(20) 8.90 gをメタノール 445 mlに溶解した
後、36℃で16時間反応させた。反応液を減圧濃縮
し、化合物(21) 7.80 gを得た。 化合物(21)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4777NO16S (3) マススペクトル (SIMS) : m/z 944 (M+H)+ (4) 比旋光度 : [α]D 16 -58°(c1.0, CH3OH) (5) 融点 : 明瞭な融点を示さず、113〜116℃付
近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 5.10(br
d, 3-H), 3.25(br d, 4-H), 3.57(s, 4-OCH3), 3.96(br
d, 5-H), 0.92(br dt, 7-H), 1.57(br dt, 7-H), 2.03
(m, 8-H), 5.07(dd, 9-H), 5.58(dd, 10-H), 6.71(dd,
11-H), 6.09(br dd, 12-H), 5.86(ddd, 13-H), 2.46(br
dt, 14-H), 5.00(ddq, 15-H), 1.26(d, 16-H3), 2.62
(br dd, 17-H), 2.84(br dd, 17-H), 9.66(s, 18-H),
0.95(d, 19-H3), 2.29(s, 3-OCOCH3),1.10(t, 9-OCOCH2
CH3 ), 4.49(d, 1'-H), 3.21(dd, 2'-H), 2.42(t, 3'-
H), 3.42(t, 4'-H), 3.28(dq, 5'-H), 1.15(d, 6'-H3),
2.57(s, 3'-N(CH3)2), 4.92(d,1"-H), 1.74(dd, 2"-Ha
x), 1.20(s, 3"-CH3), 4.55(dq, 5"-H), 1.08(d, 6"-
H3), 4.52(d, 3"-OCH 2SCH3), 4.64, 4.66(2×d, 4"-H,
3"-OCH 2SCH3), 2.19(s, 3"-OCH2SCH3 ), 0.98(d, 4"-OCO
CH2CH(CH3)2 )
Example 21 Compound (21) (in the formula (VII), R 1 is a methyl group.
R 4 is an isovaleryl group and R 5 is propionyl.
Le compounds represented by groups) of the preparation the compound (20) 8.90 g was dissolved in methanol 445 ml, was allowed to react for 16 hours at 36 ° C.. The reaction solution was concentrated under reduced pressure to obtain 7.80 g of compound (21). Physicochemical properties of compound (21) (1) Color and shape: colorless solid (2) Molecular formula: C 47 H 77 NO 16 S (3) Mass spectrum (SIMS): m / z 944 (M + H) + (4) ) Specific rotation: [α] D 16 -58 ° (c1.0, CH 3 OH) (5) Melting point: No melting point, melting at around 113-116 ° C (6) 1 H NMR spectrum (400MHz , CDCl 3 ) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 5.10 (br
d, 3-H), 3.25 (br d, 4-H), 3.57 (s, 4-OCH 3 ), 3.96 (br
d, 5-H), 0.92 (br dt, 7-H), 1.57 (br dt, 7-H), 2.03
(m, 8-H), 5.07 (dd, 9-H), 5.58 (dd, 10-H), 6.71 (dd,
11-H), 6.09 (br dd, 12-H), 5.86 (ddd, 13-H), 2.46 (br
dt, 14-H), 5.00 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.62
(br dd, 17-H), 2.84 (br dd, 17-H), 9.66 (s, 18-H),
0.95 (d, 19-H 3 ), 2.29 (s, 3-OCOCH 3 ), 1.10 (t, 9-OCOCH 2
C H 3 ), 4.49 (d, 1'-H), 3.21 (dd, 2'-H), 2.42 (t, 3'-
H), 3.42 (t, 4'-H), 3.28 (dq, 5'-H), 1.15 (d, 6'-H 3 ),
2.57 (s, 3'-N (CH 3 ) 2 ), 4.92 (d, 1 "-H), 1.74 (dd, 2" -Ha
x), 1.20 (s, 3 "-CH 3 ), 4.55 (dq, 5" -H), 1.08 (d, 6 "-
H 3 ), 4.52 (d, 3 "-OC H 2 SCH 3 ), 4.64, 4.66 (2 × d, 4" -H,
3 "-OC H 2 SCH 3 ), 2.19 (s, 3" -OCH 2 SC H 3 ), 0.98 (d, 4 "-OCO
CH 2 CH (C H 3 ) 2 )

【0058】実施例22化合物(22)(式(VIII)において、R1がメチル基で
表され、R4がイソバレリル基で表され、R5がプロピオニ
ル基で表される化合物)の製造法 化合物(21) 1.50 gをエタノール 35 mlに溶解した
後、ラネーニッケル 38mlを実施例1と同様の方法で活
性をコントロールし、 40 mlのエタノールと共に上記溶
液に加えた。これを室温で20分間激しく撹拌した後、
不溶物を濾過し、1%(v/v)の濃アンモニア水を含むエタ
ノール各 50 mlで2回洗浄した。濾液と洗液を合わせ、
減圧濃縮して得られた残さ 1.00 gをシリカゲルカラム
クロマトグラフィー(100 g:ヘキサン−酢酸エチル(1:
1))で精製して化合物(22) 220 mg得た。 化合物(22)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4675NO16 (3) マススペクトル (SIMS) : m/z 898 (M+H)+ (4) 比旋光度 : [α]D 15 -61°(c1.0, CH3OH) (5) 明瞭な融点を示さず、115〜118℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.75(dd, 2-H), 5.11(br
d, 3-H), 3.24(br d, 4-H), 3.58(s, 4-OCH3), 3.96(br
d, 5-H), 0.92(br dt, 7-H), 1.58(br dt, 7-H), 2.03
(m, 8-H), 5.07(dd, 9-H), 5.58(dd, 10-H), 6.71(dd,
11-H), 6.09(br dd, 12-H), 5.86(ddd, 13-H), 2.17(d
t, 14-H), 2.46(br dt, 14-H), 5.00(ddq, 15-H), 1.26
(d, 16-H3),2.62(br dd, 17-H), 2.85(br dd, 17-H),
9.66(s, 18-H), 0.95(d, 19-H3), 2.29(s, 3-OCOCH3),
1.11(t, 9-OCOCH2CH3 ), 4.51(d, 1'-H), 3.19(dd, 2'-
H), 2.41(t, 3'-H), 3.45(t, 4'-H), 3.29(dq, 5'-H),
1.16(d, 6'-H3), 2.57(s, 3'-N(CH3)2), 4.93(d, 1"-
H), 1.67(dd, 2"-Hax), 1.11(s, 3"-CH3), 4.73(d, 4"-
H),4.54(dq, 5"-H), 1.08(d, 6"-H3), 3.26(s, 3"-OC
H3), 0.97(d, 4"-OCOCH2CH(CH3)2 )
Example 22 Compound (22) (in the formula (VIII), R 1 is a methyl group.
R 4 is an isovaleryl group and R 5 is propionyl.
Le compounds represented by groups) of the production method of compound (21) After the 1.50 g were dissolved in ethanol 35 ml, Raney nickel 38ml controlling the activity in the same manner as in Example 1, the above solution with 40 ml of ethanol added. After stirring it vigorously for 20 minutes at room temperature,
The insoluble material was filtered and washed twice with 50 ml of ethanol each containing 1% (v / v) concentrated aqueous ammonia. Combine the filtrate and wash,
1.00 g of the residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography (100 g: hexane-ethyl acetate (1:
The compound (22) (220 mg) was obtained after purification by 1)). Physicochemical properties of compound (22) (1) Color and shape: colorless solid (2) Molecular formula: C 46 H 75 NO 16 (3) Mass spectrum (SIMS): m / z 898 (M + H) + (4) Specific rotation: [α] D 15 -61 ° (c1.0, CH 3 OH) (5) No clear melting point, melting around 115-118 ° C (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.26 (br d, 2-H), 2.75 (dd, 2-H), 5.11 (br
d, 3-H), 3.24 (br d, 4-H), 3.58 (s, 4-OCH 3 ), 3.96 (br
d, 5-H), 0.92 (br dt, 7-H), 1.58 (br dt, 7-H), 2.03
(m, 8-H), 5.07 (dd, 9-H), 5.58 (dd, 10-H), 6.71 (dd,
11-H), 6.09 (br dd, 12-H), 5.86 (ddd, 13-H), 2.17 (d
t, 14-H), 2.46 (br dt, 14-H), 5.00 (ddq, 15-H), 1.26
(d, 16-H 3 ), 2.62 (br dd, 17-H), 2.85 (br dd, 17-H),
9.66 (s, 18-H), 0.95 (d, 19-H 3 ), 2.29 (s, 3-OCOCH 3 ),
1.11 (t, 9-OCOCH 2 C H 3 ), 4.51 (d, 1'-H), 3.19 (dd, 2'-
H), 2.41 (t, 3'-H), 3.45 (t, 4'-H), 3.29 (dq, 5'-H),
1.16 (d, 6'-H 3 ), 2.57 (s, 3'-N (CH 3 ) 2 ), 4.93 (d, 1 "-
H), 1.67 (dd, 2 "-Hax), 1.11 (s, 3" -CH 3 ), 4.73 (d, 4 "-
H), 4.54 (dq, 5 "-H), 1.08 (d, 6" -H 3 ), 3.26 (s, 3 "-OC
H 3 ), 0.97 (d, 4 "-OCOCH 2 CH (C H 3 ) 2 )

【0059】実施例23化合物(23)(式(VIII)において、R1がエチル基で
表され、R4がプロピオニル基で表され、R5がプロピオニ
ル基で表される化合物)の製造法 化合物(12) 20 mgに無水トルエン 1.0 mlを加え溶
解し、無水ピリジン 8.4μlを加えた後、室温で20分
間撹拌した。反応混合物に酢酸エチル 10 ml及びトリエ
チルアミン 7.8μlを加え抽出し、酢酸エチル層を水 10
mlで2回洗浄した後、無水硫酸ナトリウムで乾燥後こ
れを濾過した。濾液を減圧濃縮して得られた残さ 28 mg
を分離用TLC(展開系:クロロホルム−メタノール−濃
アンモニア水(30:1:0.1))で精製し、化合物(23) 1
3 mgを得た。 化合物(23)の理化学的性状 (1) 色および形状 : 無色固体 (2) 分子式 : C4573NO16 (3) マススペクトル (EIMS) : m/z 883 (M)+ (4) 比旋光度 : [α]D 22 -72°(c1.0, CH3OH) (5) 明瞭な融点を示さず、114〜117℃付近で熔融 (6) 1H NMRスペクトル (400MHz, CDCl3) δ
(ppm) : 2.26(br d, 2-H), 2.74(dd, 2-H), 5.12(br
d, 3-H), 3.24(br d, 4-H), 3.56(s, 4-OCH3), 3.94(br
d, 5-H), 0.90(br ddd, 7-H), 1.57(br dt, 7-H), 2.0
2(m, 8-H), 5.09(dd, 9-H), 5.58(dd, 10-H), 6.74(dd,
11-H), 6.09(br dd, 12-H), 5.88(ddd, 13-H), 2.17(d
t, 14-H), 4.98(ddq, 15-H), 1.26(d, 16-H3), 2.60(br
dd, 17-H),2.83(br dd, 17-H), 9.65(br s, 18-H), 0.
96(d, 19-H3), 2.51(dq, 3-OCOCH 2CH3), 2.68(dq, 3-OC
OCH 2CH3), 1.21(t, 3-OCOCH2CH3 ), 2.30(q, 9-OCOCH2 CH
3),1.11(t, 9-OCOCH2CH3 ), 4.51(d, 1'-H), 3.21(dd,
2'-H), 3.45(t, 4'-H), 3.28(dq, 5'-H), 1.16(d, 6'-H
3), 2.58(s, 3'-N(CH3)2), 4.93(d, 1"-H), 1.67(dd,2"
-Hax), 2.29(d, 2"-Heq), 1.10(s, 3"-CH3), 4.72(d,
4"-H), 4.53(dq, 5"-H), 1.08(d, 6"-H3), 3.26(s, 3"-
OCH3), 2.43(apparent q, 3-OCOCH 2CH3), 2.44(apparen
t q, 3-OCOCH 2CH3), 1.17(t, 3-OCOCH2CH3 )
Example 23 Compound (23) (in formula (VIII), R 1 is an ethyl group
R 4 is a propionyl group and R 5 is a propionyl group.
Method for producing compound represented by diol group ) To 20 mg of compound (12), 1.0 ml of anhydrous toluene was added and dissolved, and 8.4 μl of anhydrous pyridine was added, followed by stirring at room temperature for 20 minutes. 10 ml of ethyl acetate and 7.8 μl of triethylamine were added to the reaction mixture for extraction, and the ethyl acetate layer was washed with water.
It was washed twice with ml, dried over anhydrous sodium sulfate, and filtered. 28 mg of residue obtained by concentrating the filtrate under reduced pressure
Was purified by preparative TLC (developing system: chloroform-methanol-concentrated aqueous ammonia (30: 1: 0.1)) to give compound (23) 1
3 mg was obtained. Physicochemical properties of compound (23) (1) Color and shape: colorless solid (2) Molecular formula: C 45 H 73 NO 16 (3) Mass spectrum (EIMS): m / z 883 (M) + (4) Specific rotation Degree: [α] D 22 -72 ° (c1.0, CH 3 OH) (5) Melting around 114 to 117 ° C without showing clear melting point (6) 1 H NMR spectrum (400MHz, CDCl 3 ) δ
(ppm): 2.26 (br d, 2-H), 2.74 (dd, 2-H), 5.12 (br
d, 3-H), 3.24 (br d, 4-H), 3.56 (s, 4-OCH 3 ), 3.94 (br
d, 5-H), 0.90 (br ddd, 7-H), 1.57 (br dt, 7-H), 2.0
2 (m, 8-H), 5.09 (dd, 9-H), 5.58 (dd, 10-H), 6.74 (dd,
11-H), 6.09 (br dd, 12-H), 5.88 (ddd, 13-H), 2.17 (d
t, 14-H), 4.98 (ddq, 15-H), 1.26 (d, 16-H 3 ), 2.60 (br
dd, 17-H), 2.83 (br dd, 17-H), 9.65 (br s, 18-H), 0.
96 (d, 19-H 3 ), 2.51 (dq, 3-OCOC H 2 CH 3 ), 2.68 (dq, 3-OC
OC H 2 CH 3 ), 1.21 (t, 3-OCOCH 2 C H 3 ), 2.30 (q, 9-OCOC H 2 CH
3 ), 1.11 (t, 9-OCOCH 2 C H 3 ), 4.51 (d, 1'-H), 3.21 (dd,
2'-H), 3.45 (t, 4'-H), 3.28 (dq, 5'-H), 1.16 (d, 6'-H)
3 ), 2.58 (s, 3'-N (CH 3 ) 2 ), 4.93 (d, 1 "-H), 1.67 (dd, 2"
-Hax), 2.29 (d, 2 "-Heq), 1.10 (s, 3" -CH 3 ), 4.72 (d,
4 "-H), 4.53 (dq, 5" -H), 1.08 (d, 6 "-H 3 ), 3.26 (s, 3"-
OCH 3 ), 2.43 (apparent q, 3-OCOC H 2 CH 3 ), 2.44 (apparen
tq, 3-OCOC H 2 CH 3 ), 1.17 (t, 3-OCOCH 2 C H 3 )

【0060】[0060]

【発明の効果】第一の本発明の効果とするところは、有
用な新規16員環マクロリド誘導体の造出にある。即ち
本発明で得られる一般式(VIII)及び(IX)で表される
化合物は臨床上重要なグラム陽性菌に対して、優れた抗
菌力を有している。はじめに、一般式(VIII)で表され
る化合物のうち9位の水酸基がアセチル化された化合物
(2)及び(6)は、優れた16員環マクロリド抗菌剤
であるミオカマイシン(MOM)(ジャーナル・オブ・ア
ンチビオチックス, 29(5), 536(1976))と比較して、同
等あるいは同等以上のin vitroの抗菌活性を有してい
る。なお化合物(6)は化合物(2)と比較して、Bran
hamella catarrhalisに対する抗菌活性が若干優れてい
た。ところで、ラクトン環9位の水酸基がプロピオニル
化された化合物(22)及び(23)も、実用上充分な
抗菌活性を有している。一方ラクトン環9位の水酸基が
1-エトキシエチル化されている化合物(11H)、(1
1L)及び(17)の抗菌活性は、相当するラクトン環
の9位が遊離の水酸基である化合物(12)及び(1
8)と比較して劣るものの、それ自体有効な抗菌力を有
していた。
The first effect of the present invention is to create a useful novel 16-membered ring macrolide derivative. That is, the compounds represented by the general formulas (VIII) and (IX) obtained in the present invention have excellent antibacterial activity against clinically important Gram-positive bacteria. First, among the compounds represented by the general formula (VIII), the compounds (2) and (6) in which the 9-position hydroxyl group is acetylated are myocamycin (MOM), which is an excellent 16-membered ring macrolide antibacterial agent.・ Compared to that of Antibiotics, 29 (5), 536 (1976)), it has equivalent or higher in vitro antibacterial activity. Note Compound (6) is compared with the compound (2), Bran
The antibacterial activity against hamella catarrhalis was slightly superior. Incidentally, the compounds (22) and (23) in which the hydroxyl group at the 9-position of the lactone ring is propionylated also have practically sufficient antibacterial activity. On the other hand, the hydroxyl group at the 9-position of the lactone ring
1-ethoxyethylated compound (11H), (1
The antibacterial activities of (1L) and (17) are as follows: Compounds (12) and (1
Although inferior to 8), it had effective antibacterial activity.

【0061】また本発明製造法により合成した式(I)
で表される化合物は、マウス感染治療実験において既存
の16員環マクロリド抗菌剤と比べ優れたin vivo効果
を発揮する。その一例として本法で製造した化合物
(2)は、肺炎球菌Streptococcus pneumoniae DP-1 Ty
pe1によるマウス感染治療実験においてMOMの1/4以下の
量で、さらにロキタマイシン(ジャーナル・オブ・アン
チビオチックス, 34(8), 1001(1981))の1/8以下の量で
同等の感染治療効果を示した。この優れた効果は、3"位
の3級水酸基がアシル基によりエステル結合しているの
ではなく、メチル基によりエーテル結合していることに
直接関与している。即ち化合物(2)の生体内代謝物の
一つである3"-O-メチルミデカマイシンM1(3"-O-メチル
-3-O-プロピオニルロイコマイシンV)(特願平5-16941
8)が、MOMの相当物質であるミデカマイシンM1(ジャー
ナル・オブ・バクテリオロジー, 174(15), 5141(1992),
特開昭48-10288)と比較し一段と優れた抗菌活性を有
していることに、卓越したin vivo効果の一因がある。
ところで4"位の水酸基に結合したイソバレリル基は、ラ
ット血漿中において、プロピオニル基よりも切断されに
くいことが報告されている(薬学雑誌, 102(8), 781(19
82))。それゆえ実際に本発明化合物(6)を、マウス
感染治療実験に供すると、化合物(6)は化合物(2)
と比較して同等以上のin vivo効果を示した。
The formula (I) synthesized by the production method of the present invention
The compound represented by the formula (6) exhibits a superior in vivo effect in a mouse infection treatment experiment as compared with the existing 16-membered ring macrolide antibacterial agent. As an example, the compound (2) produced by this method is Streptococcus pneumoniae DP-1 Ty.
In a mouse infection treatment experiment with pe1, an equivalent infection treatment was performed with an amount of 1/4 or less of MOM and 1/8 or less of rokitamycin (Journal of Antibiotics, 34 (8), 1001 (1981)). Showed the effect. This excellent effect is directly related to the fact that the tertiary hydroxyl group at the 3 "-position is not ester-bonded by an acyl group but ether-linked by a methyl group. That is, in vivo of compound (2) One of the metabolites, 3 "-O-methyl midecamycin M 1 (3" -O-methyl
-3-O-propionyl leucomycin V) (Japanese Patent Application No. 5-16941)
8) is the equivalent substance of MOM, midecamycin M 1 (Journal of Bacteriology, 174 (15), 5141 (1992),
The fact that the antibacterial activity is far superior to that of JP-A-48-10288) is one reason for the excellent in vivo effect.
By the way, it has been reported that the isovaleryl group bonded to the 4 "-position hydroxyl group is less likely to be cleaved in rat plasma than the propionyl group (Pharmaceutical Journal, 102 (8), 781 (19).
82)). Therefore, when the compound (6) of the present invention is actually subjected to a mouse infection treatment experiment, the compound (6) is converted to the compound (2).
The in vivo effect was equal to or higher than that of.

【0062】第二の本発明の効果とするところは、一般
式(III)で表される化合物を、一般式(II)で表され
る天然に存在する公知の16員環マクロリド抗生物質を
出発原料として、3"-メチルチオメチルエーテル合成中
間体を経由することにより、グリコシル化反応を経由す
ることなく、4工程ないしは6工程で効率良く調製する
新規製造法を提供することにある。例えば、以前本発明
者らがミデカマイシンA3とエリスロマイシンを出発原料
として本発明化合物(2)を調製した際は、グリコシル
化反応を含む9工程の化学反応と1段階の微生物変換を
実施して、ミデカマイシンA3からの全収率は最高でも5
%には満たなかった。しかしながら本発明の新規製造法
によれば、メデマイシンを出発原料として全収率20%前
後で化合物(2)を合成することが可能となった。
The second effect of the present invention is that the compound represented by the general formula (III) is started from a known naturally-occurring 16-membered macrolide antibiotic represented by the general formula (II). The purpose of the present invention is to provide a novel production method in which a 3 "-methylthiomethyl ether synthetic intermediate is used as a raw material to efficiently prepare in 4 to 6 steps without passing through a glycosylation reaction. When the present inventors prepared the compound (2) of the present invention using midecamycin A 3 and erythromycin as starting materials, 9 steps of chemical reaction including glycosylation reaction and 1-step microbial conversion were carried out to obtain midecamycin A 3 The total yield from
It was less than%. However, according to the novel production method of the present invention, it became possible to synthesize compound (2) using medemycin as a starting material in a total yield of about 20%.

【0063】第三の本発明の効果とするところは、化学
的安定性の良好でない化合物に存在する3級水酸基へあ
くまで穏和な反応条件により間接的にメチル基を導入す
る一般的な方法を提供することにある。メチルチオメチ
ルエーテル化された水酸基をメトキシ基に変換する反応
それ自身は前述した如く既に知られていた(カーボハイ
ドレート・リサーチ, 7, 474(1968))が、3級水酸基に
当該化学変換を適用した例はあまり知られていない。さ
らに二重結合或いは遊離のアルデヒド基等接触還元条件
に反応性の富む官能基を有する化合物に対し、本反応を
展開した例は殆ど報告されていない。
The third effect of the present invention is to provide a general method for indirectly introducing a methyl group into a tertiary hydroxyl group present in a compound having poor chemical stability under mild reaction conditions. To do. The reaction itself for converting a methylthiomethyl etherified hydroxyl group into a methoxy group has already been known as described above (Carbohydrate Research, 7 , 474 (1968)), but the chemical conversion is applied to the tertiary hydroxyl group. There are few known examples. Furthermore, there have been few reports of developing this reaction for a compound having a functional group having a high reactivity under a catalytic reduction condition such as a double bond or a free aldehyde group.

【0064】第四の本発明の効果とするところは、16
員環マクロリド抗生物質の誘導体研究におけるラクトン
環9位の水酸基の効率的な保護基を提供することにあ
る。天然より得られる化合物を出発原料として化学反応
により優れた誘導体を製造する際には、一般に特定の官
能基、例えばアミノ基或いは水酸基等を保護する必要の
ある場合が少なくない。16員環マクロリド化合物の合
成化学的誘導体研究において、9位の水酸基に関する能
率の良い保護基の使用例はほとんど知られていなかっ
た。本発明者らは不斉炭素を有するアセタール系の保護
基、特に1-エトキシエチル基が、保護基としての特性を
充分に備えていることを実証した。
The effect of the fourth invention is 16
It is intended to provide an efficient protecting group for the hydroxyl group at the 9-position of the lactone ring in the study of derivatives of a membered ring macrolide antibiotic. When producing an excellent derivative by a chemical reaction using a compound obtained from nature as a starting material, it is often necessary to protect a specific functional group such as an amino group or a hydroxyl group. In the study of synthetic chemical derivatives of 16-membered ring macrolide compounds, few examples of the use of an efficient protecting group for the 9-position hydroxyl group were known. The present inventors have demonstrated that an acetal-based protecting group having an asymmetric carbon atom, particularly a 1-ethoxyethyl group, has sufficient properties as a protecting group.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 柴原 聖至 神奈川県横浜市港北区師岡町760番地 明 治製菓株式会社薬品総合研究所内 (72)発明者 井上 重治 神奈川県横浜市港北区師岡町760番地 明 治製菓株式会社薬品総合研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Seiji Shibahara 760 Shimooka-cho, Kohoku-ku, Yokohama-shi, Kanagawa Meiji Confectionery Co., Ltd., Pharmaceutical Research Laboratory (72) Inventor Shigeharu Inoue 760 Shimooka-cho, Kohoku-ku, Yokohama-shi, Kanagawa Address Meiji Seika Co., Ltd. Pharmaceutical Research Institute

Claims (9)

【特許請求の範囲】[Claims] 【請求項1】 次の式(I) 【化1】 [式中、R1は炭素数1〜3の直鎖のアルキル基であり、
R2は水素原子又は水酸基を修飾(或いは保護)する置換
基であり、R3は水素原子又は炭素数2〜5の直鎖又は分
枝鎖の脂肪族アシル基]で表される化合物、又はその薬
学的に許容し得る塩。
1. The following formula (I): [In the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms,
R 2 is a hydrogen atom or a substituent that modifies (or protects) a hydroxyl group, R 3 is a compound represented by a hydrogen atom or a linear or branched aliphatic acyl group having 2 to 5 carbon atoms, or A pharmaceutically acceptable salt thereof.
【請求項2】 請求項1の式(I)において、R1がメチ
ル基で表され、R2がアセチル基で表され、R3がイソバレ
リル基で表される化合物、又はその薬学的に許容し得る
塩。
2. A compound represented by the formula (I) according to claim 1, wherein R 1 is a methyl group, R 2 is an acetyl group and R 3 is an isovaleryl group, or a pharmaceutically acceptable compound thereof. Possible salt.
【請求項3】 請求項1の式(I)において、R1がエチ
ル基で表され、R2が1-エトキシエチル基で表され、R3
プロピオニル基で表される化合物、又はその薬学的に許
容し得る塩。
3. A compound represented by formula (I) according to claim 1, wherein R 1 is an ethyl group, R 2 is a 1-ethoxyethyl group, and R 3 is a propionyl group, or a pharmaceutical thereof. Acceptable salt.
【請求項4】 請求項1の式(I)において、R1がメチ
ル基で表され、R2が1-エトキシエチル基で表され、R3
イソバレリル基で表される化合物、又はその薬学的に許
容し得る塩。
4. A compound represented by the formula (I) of claim 1, wherein R 1 is a methyl group, R 2 is a 1-ethoxyethyl group, and R 3 is an isovaleryl group, or a pharmaceutical thereof. Acceptable salt.
【請求項5】 請求項1の式(I)において、R1がメチ
ル基で表され、R2が水素原子で表され、R3がイソバレリ
ル基で表される化合物、又はその薬学的に許容し得る
塩。
5. A compound represented by formula (I) according to claim 1, wherein R 1 is a methyl group, R 2 is a hydrogen atom and R 3 is an isovaleryl group, or a pharmaceutically acceptable compound thereof. Possible salt.
【請求項6】 請求項1の式(I)において、R1がメチ
ル基で表され、R2がプロピオニル基で表され、R3がイソ
バレリル基で表される化合物、又はその薬学的に許容し
得る塩。
6. A compound represented by the formula (I) of claim 1, wherein R 1 is a methyl group, R 2 is a propionyl group, and R 3 is an isovaleryl group, or a pharmaceutically acceptable compound thereof. Possible salt.
【請求項7】 請求項1の式(I)において、R1がエチ
ル基で表され、R2がプロピオニル基で表され、R3がプロ
ピオニル基で表される化合物、又はその薬学的に許容し
得る塩。
7. A compound represented by the formula (I) of claim 1, wherein R 1 is an ethyl group, R 2 is a propionyl group, and R 3 is a propionyl group, or a pharmaceutically acceptable compound thereof. Possible salt.
【請求項8】 次の式(II) 【化2】 [式中、R1は炭素数1〜3の直鎖のアルキル基であり、
R4は炭素数2〜5の直鎖又は分枝鎖の脂肪族アシル基]
で表される化合物、又はその塩を出発原料として用い
て、次の式(III) 【化3】 [式中、R1は炭素数1〜3の直鎖のアルキル基であり、
R2は水素原子又は水酸基を修飾(或いは保護)する置換
基であり、R4は炭素数2〜5の直鎖又は分枝鎖の脂肪族
アシル基]で表される化合物、又はその塩を得るための
効率的製造法。
8. The following formula (II): [In the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms,
R 4 is a linear or branched aliphatic acyl group having 2 to 5 carbon atoms]
Using a compound represented by the following formula or a salt thereof as a starting material, the following formula (III): [In the formula, R 1 is a linear alkyl group having 1 to 3 carbon atoms,
R 2 is a hydrogen atom or a substituent that modifies (or protects) a hydroxyl group, and R 4 is a compound represented by a linear or branched aliphatic acyl group having 2 to 5 carbon atoms, or a salt thereof. Efficient manufacturing method to obtain.
【請求項9】 16員環マクロリド誘導体の化学合成等
において、ラクトン環の9位水酸基の保護基として不斉
炭素を有するアセタール系置換基、例えば1-エトキシエ
チル基、テトラヒドロフラニル基或いはテトラヒドロピ
ラニル基等を用いる方法。
9. An acetal-based substituent having an asymmetric carbon atom such as a 1-ethoxyethyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group as a protective group for the 9-position hydroxyl group of the lactone ring in the chemical synthesis of a 16-membered ring macrolide derivative. Method using a group.
JP6145125A 1993-07-08 1994-06-27 New 16-membered ring macrolide derivative and its efficient production Pending JPH0812696A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP6145125A JPH0812696A (en) 1994-06-27 1994-06-27 New 16-membered ring macrolide derivative and its efficient production
CA002127578A CA2127578A1 (en) 1993-07-08 1994-07-07 16-membered macrolide derivatives and process for producing the same
CN94115983A CN1046534C (en) 1993-07-08 1994-07-08 16-membered macrolide derivatives and process for producing the same
EP94110679A EP0633266B1 (en) 1993-07-08 1994-07-08 16-Membered macrolide derivatives and process for producing the same
AT94110679T ATE165604T1 (en) 1993-07-08 1994-07-08 16-MEMBER MACROLIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ES94110679T ES2115816T3 (en) 1993-07-08 1994-07-08 16-LINK MACROLID DERIVATIVES AND THEIR PREPARATION PROCEDURE.
US08/271,996 US5602106A (en) 1993-07-08 1994-07-08 16-membered macrolide derivatives
DE69409874T DE69409874T2 (en) 1993-07-08 1994-07-08 16-link macrolide derivatives and process for their preparation
KR1019940016581A KR100360568B1 (en) 1993-07-08 1994-07-08 16-membered ring macrolide derivative and method for manufacturing the same
CN98116380A CN1093134C (en) 1993-07-08 1998-07-23 16-membered marcrolide derivatives and process for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6145125A JPH0812696A (en) 1994-06-27 1994-06-27 New 16-membered ring macrolide derivative and its efficient production

Publications (1)

Publication Number Publication Date
JPH0812696A true JPH0812696A (en) 1996-01-16

Family

ID=15377986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6145125A Pending JPH0812696A (en) 1993-07-08 1994-06-27 New 16-membered ring macrolide derivative and its efficient production

Country Status (1)

Country Link
JP (1) JPH0812696A (en)

Similar Documents

Publication Publication Date Title
RU2230748C2 (en) Method for preparing clarithromycin as crystals of form ii
FI80708B (en) FOERFARANDE FOER SELEKTIV METYLATION AV DERIVAT AV ERYTROMYCIN A.
US4196280A (en) Novel macrolactone derivatives and process of producing them
DK157495B (en) ANALOGY PROCEDURE FOR PREPARING 4AE-EPI-ERYTHROMYCINE A OR DERIVATIVES THEREOF
US4150220A (en) Semi-synthetic 4&#34;-erythromycin A derivatives
CA1306249C (en) Tylosin derivatives and processes for producing the same
EP0202111B1 (en) Antibacterial mycaminosyl tylonolide derivatives and their production
JP2013537213A (en) Novel process for producing 9-deoxo-9a-aza-9a-homoerythromycin A in which C-4 &#34;of cladinose ring is modified with an epoxide group
JP3063943B2 (en) Novel 16-membered ring macrolide derivatives having sustained antibacterial activity in plasma, intermediates for synthesizing the same and methods for producing them
JPH0812696A (en) New 16-membered ring macrolide derivative and its efficient production
EP0627443B1 (en) 3,4&#39;-dideoxymycaminosyltylonolide derivative and production thereof
NO320704B1 (en) New 8A and 9A-15 ring lactams, their use and process for their preparation, as well as pharmaceutical preparation.
JPH07149788A (en) New 16-membered ring macrolide derivative and its efficient production process
US4255564A (en) Novel macrolactone derivatives and process of producing them
JPH08301894A (en) New efficient production of 16-membered ring macrolide derivative
GB1585315A (en) Erythromycin a derivatives
JPH07309889A (en) New 16-membered cyclic macrolide derivative and its new production
KR100361397B1 (en) Process for producing clarithromycin using erythromycin a 9-o-tropyloxime derivatives
JPWO2003068792A1 (en) Method for producing erythromycin A derivative
JPH0529038B2 (en)
JPH07330791A (en) Mew 16-membered macrolide derivative and its new comprehensive production
EP0490311B1 (en) Derivatives of 10,11,12,13-tetra-hydrodesmycosin, processes for preparation, and use thereof in obtaining pharmaceuticals
JP2009513526A (en) Steroid-modified chacotriose and soratriose
KR20020013081A (en) A process for preparing Eiprubicin and Pharmaceutically acceptable salt thereof
KR20020013080A (en) A process for preparing Eiprubicin and Pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051213